Amphastar Pharmaceuticals (AMPH) 10-K 26 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 18, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Amphastar Pharmaceuticals, Inc.
Document Type	10-K
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		44,564,667
Entity Public Float			$430,686,276
Amendment Flag	FALSE
Entity Central Index Key	1297184
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets:
Cash and cash equivalents	$67,828	$53,587
Restricted cash and restricted short-term investments	1,495	1,325
Accounts receivable, net	22,852	24,585
Inventories, net	82,332	69,916
Income tax refund and deposits	273	2,429
Prepaid expenses and other assets	3,683	5,033
Deferred tax assets	19,533	16,096
Total current assets	197,996	172,971
Property, plant, and equipment, net	138,289	116,619
Goodwill and intangible assets, net	42,565	40,163
Other assets	3,588	2,877
Deferred tax assets	6,932	6,118
Total assets	389,370	338,748
Current Liabilities:
Accounts payable	10,161	20,380
Accrued liabilities	13,144	7,628
Income taxes payable	3,123	2,847
Accrued payroll and related benefits	11,449	9,161
Current portion of product return accrual	1,918	2,639
Current portion of deferred revenue	14,013	643
Current portion of long-term debt and capital leases	7,594	22,104
Current portion of deferred tax liability	1,193
Total current liabilities	62,595	65,402
Long-term product return accrual	490	1,953
Long-term reserve for income tax liability	499
Long-term deferred revenue	1,982	2,625
Long-term debt and capital leases, net of current portion	36,106	10,069
Deferred tax liabilities	5,838	7,154
Total liabilities	107,510	87,203
Stockholders’ equity:
Preferred stock: par value $.0001; authorized shares—20,000,000; none issued	0	0
Common stock; par value $.0001; authorized shares—300,000,000; issued and outstanding shares—44,646,767 and 38,765,940 at December 31, 2014 and December 31, 2013, respectively	4	4
Additional paid-in capital	220,745	177,732
Retained earnings	63,110	73,809
Accumulated other comprehensive loss	-1,654
Treasury stock	-345
Total stockholders’ equity	281,860	251,545
Total liabilities and stockholders’ equity	$389,370	$338,748

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Common stock; par value (in Dollars per share)	$0.00	$0.00
Common stock; authorized shares	300,000,000	300,000,000
Common stock; shares issued	44,646,767	38,765,940
Common stock; outstanding shares	44,646,767	38,765,940

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net revenues	$210,461	$229,681	$204,323
Cost of revenue	159,205	142,725	114,020
Gross profit	51,256	86,956	90,303
Operating expenses:
Selling, distribution, and marketing	5,564	5,349	4,426
General and administrative	34,809	30,972	27,223
Research and development	28,427	33,019	31,163
Impairment of long-lived assets	439	126	2,094
Total operating expenses	69,239	69,466	64,906
Income (loss) from operations	-17,983	17,490	25,397
Non-operating income (expense):
Interest income	243	187	242
Interest expense	-609	-958	-784
Other income, net	201	508	1,023
Total non-operating income (expense), net	-165	-263	481
Income (loss) before income taxes	-18,148	17,227	25,878
Income tax expense (benefit)	-7,449	5,365	7,784
Net income (loss)	($10,699)	$11,862	$18,094
Net income (loss) per common share:
Basic (in Dollars per share)	($0.25)	$0.31	$0.47
Diluted (in Dollars per share)	($0.25)	$0.31	$0.46
Weighted-average shares used to compute net income (loss) per common share:
Basic (in Shares)	41,957	38,712	38,580
Diluted (in Shares)	41,957	38,883	38,940

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net income (loss)	($10,699)	$11,862	$18,094
Accumulated other comprehensive income (loss)
Foreign currency translation adjustment	-1,810
Change in actuarial valuation	156
Accumulated other comprehensive loss	-1,654
Total comprehensive income (loss)	($12,353)	$11,862	$18,094

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Nonemployee [Member]	Employee [Member]	Total
In Thousands, except Share data		Nonemployee [Member]	Employee [Member]
Balance at Dec. 31, 2011	$4			$164,661	$43,853					$208,518
Balance (in Shares) at Dec. 31, 2011	38,510,314
Net income (loss)					18,094					18,094
Reduction of excess tax benefit of share-based awards				-120						-120
Exercise of stock options				333						333
Exercise of stock options (in Shares)	41,300
Issuance of common stock to employees in connection with the release of vested deferred stock units, net of common stock withheld to settle equity awards				-811						-811
Issuance of common stock to employees in connection with the release of vested deferred stock units, net of common stock withheld to settle equity awards (in Shares)	98,386
Issuance of common stock to nonemployees in connection with exercise of common stock options (in Shares)	31,660
Share-based compensation expense		750	6,675					750	6,675
Balance at Dec. 31, 2012	4			171,488	61,947					233,439
Balance (in Shares) at Dec. 31, 2012	38,681,660
Net income (loss)					11,862					11,862
Reduction of excess tax benefit of share-based awards				-647						-647
Exercise of stock options				55						55
Exercise of stock options (in Shares)	4,200									4,200
Issuance of common stock to employees in connection with the release of vested deferred stock units, net of common stock withheld to settle equity awards				-199						-199
Issuance of common stock to employees in connection with the release of vested deferred stock units, net of common stock withheld to settle equity awards (in Shares)	14,023
Share-based compensation expense		946	6,089					946	6,089
Issuance of common stock to nonemployees (in Shares)	66,057
Balance at Dec. 31, 2013	4			177,732	73,809					251,545
Balance (in Shares) at Dec. 31, 2013	38,765,940									38,765,940
Net income (loss)					-10,699					-10,699
Accumulated other comprehensive loss						-1,654				-1,654
Reduction of excess tax benefit of share-based awards				-1,109						-1,109
Common stock issued through initial public offering				38,018						38,018
Common stock issued through initial public offering (in Shares)	5,840,000
Cost related to public offering				-3,358						-3,358
Treasury stock acquired							-345			-345
Treasury stock acquired (in Shares)							-29,400			-29,400
Exercise of stock options				571						571
Exercise of stock options (in Shares)	30,000									65,000
Issuance of common stock to employees in connection with the release of vested deferred stock units, net of common stock withheld to settle equity awards				-389						-389
Issuance of common stock to employees in connection with the release of vested deferred stock units, net of common stock withheld to settle equity awards (in Shares)	14,306
Share-based compensation expense		946	8,334					946	8,334
Issuance of common stock to nonemployees (in Shares)	25,921
Balance at Dec. 31, 2014	$4			$220,745	$63,110	($1,654)	($345)			$281,860
Balance (in Shares) at Dec. 31, 2014	44,676,167						-29,400			44,646,767

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parentheticals) (Additional Paid-in Capital [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Nonemployee [Member]
Share-based compensation expense, stock option awards	$576	$499	$412
Share-based compensation expense, DSU awards	370	447	338
Employee [Member]
Share-based compensation expense, stock option awards	6,728	5,926	6,465
Share-based compensation expense, DSU awards	$1,606	$163	$210

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash Flows From Operating Activities:
Net income (loss)	($10,699)	$11,862	$18,094
Reconciliation to net cash provided by (used in) operating activities:
Impairment of long-lived assets	439	126	2,094
Loss on disposal of property, plant, and equipment	46	91	611
Depreciation and amortization of property, plant, and equipment	12,528	11,171	9,657
Amortization of product rights, trademarks, and patents	1,920	1,907	1,840
Imputed interest accretion	163
Employee share-based compensation expense	8,334	6,089	6,675
Non-employee share-based compensation expense	946	946	750
Reserve for income tax liabilities	499	-167	-3,308
Changes in deferred taxes	-8,743	2,248	11,583
Changes in operating assets and liabilities:
Accounts receivable, net	1,210	11,824	-16,647
Inventories, net	6,565	-18,538	-25,219
Income tax refund and deposits	1,873	-576	2,399
Prepaid expenses and other assets	-88	29	180
Income taxes payable	559	-173	-2,351
Accounts payable and accrued liabilities	5,500	4,203	-8,008
Net cash provided by (used in) operating activities	21,052	31,042	-1,650
Cash Flows From Investing Activities:
Acquisition of business	-18,352
Purchases of property, plant, and equipment	-18,671	-17,642	-23,133
Capitalized labor, overhead, and interest on self-constructed assets	-1,828	-660	-603
Proceeds from the sale of property, plant and equipment			74
Purchase of trademarks and other intangible assets			-1,509
Sales of short-term investments, net		513	810
Decrease (increase) in restricted cash	-170	50	-203
Deposits and other assets, net	-752	-559	-548
Net cash used in investing activities	-39,773	-18,298	-25,112
Cash Flows From Financing Activities:
Net proceeds from issuance of common stock	38,018
Payments on repurchase of common stock	-389	-199	-811
Excess tax benefit (reduction) related to share-based compensation	-1,109	-647	-120
Net proceeds from exercise of common stock options	571	55	333
Payments on treasury stock	-345
Proceeds from borrowing under lines of credit	25,000	66,000	53,961
Repayments under lines of credit	-40,000	-71,000	-29,252
Proceeds from issuance of long-term debt	26,505
Principal payments on long-term debt	-8,216	-2,152	-874
Principal payments on short-term debt	-5,998
Net cash provided by (used in) financing activities	32,117	-9,370	23,237
Effect of exchange rate changes on cash	845
Net increase (decrease) in cash and cash equivalents	14,241	3,374	-3,525
Cash and cash equivalents at beginning of period	53,587	50,213	53,738
Cash and cash equivalents at end of period	67,828	53,587	50,213
Noncash Investing and Financing Activities:
Equipment acquired under capital leases	78	1,323
Supplemental Disclosures of Cash Flow Information:
Interest paid	2,607	1,100	1,089
Income taxes paid	436	4,158	2,078
Costs Related to Public Offering [Member]
Cash Flows From Financing Activities:
Costs related to public offering	-1,920
Deferred Offering Cost [Member]
Cash Flows From Financing Activities:
Costs related to public offering		($1,427)

Note_1_General

Note 1 - General	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1.  General
	Amphastar Pharmaceuticals, Inc., a California corporation, was incorporated on February 29, 1996 and merged with and into Amphastar Pharmaceuticals, Inc., a Delaware corporation, in July 2004 (hereinafter referred to as “the Company”). The Company is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high technical barriers to market entry. Additionally, in 2014, the Company commenced sales of insulin active pharmaceutical ingredient, or API products.  Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company’s insulin API products are primarily sold to other pharmaceutical companies for use in their own products.  The Company’s inhalation products will be primarily distributed through drug retailers once they are brought to market.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2.  Summary of Significant Accounting Policies
	Basis of Presentation
	All significant intercompany activity has been eliminated in the preparation of the consolidated financial statements. Some information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles, or GAAP, have been condensed or omitted pursuant to those rules and regulations.
	The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: International Medication Systems, Limited, or IMS; Amphastar Laboratories, Inc.; Armstrong Pharmaceuticals, Inc., or Armstrong; Amphastar Nanjing Pharmaceuticals Co., Ltd., or ANP; and Amphastar France Pharmaceuticals, S.A.S., or AFP.
	Use of Estimates
	The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for doubtful accounts and discounts, liabilities for product returns and chargebacks, reserves for excess or unsellable inventory, impairment of long-lived and intangible assets and goodwill, self-insured claims, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, fair market values of the Company’s common stock, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.
	Foreign Currency
	The functional currency of the Company and its domestic and Chinese subsidiaries is the U.S. dollar, or USD.  The Company’s Chinese subsidiary, ANP, maintains its books of record in Chinese Yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign exchange gains and losses are reflected in the Company’s statement of operations.  The Company’s French subsidiary, AFP, maintains its books of record in Euros, which is the local currency in France and has been determined to be its functional currency. These books are translated to USD at the average exchange rates during the period.  Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date.  Equity is translated at the prevailing rate of exchange at the date of the equity transactions.  Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive income (loss).  Additionally, the Company does not undertake hedging transactions to cover its foreign currency exposure.
	Comprehensive Income (Loss)
	For the Company’s recently acquired subsidiary in France, the Euro, which is the local currency, has been determined to be the functional currency. The results of the Company’s French subsidiary’s operations are translated to U.S. dollars at the average exchange rates during the period.
	For the year ended December 31, 2014, the Company includes its foreign currency translation adjustment as well as the change to its actuarial valuation on the Company’s defined benefit pension plan (see Note 16) as part of its comprehensive loss. For the years ended December 31, 2013 and 2012, net income (loss) equaled total comprehensive income (loss).
	Shipping and Handling Costs
	For the years ended December 31, 2014, 2013, and 2012, the Company included shipping and handling costs of approximately $2.5 million, $2.4 million, and $2.1 million, respectively, in selling, distribution and marketing expenses in the accompanying consolidated statements of operations.
	Research and Development Costs
	Research and development costs are charged to expense as incurred and consist of costs incurred to further the Company’s research and development activities including salaries and related employee benefits, costs associated with clinical trials, nonclinical research and development activities, regulatory activities, research-related overhead expenses and fees paid to external service providers.
	The Company may produce inventories prior to or with the expectation of receiving marketing authorization in the near term, based on operational decisions about the most effective use of existing resources. This inventory is referred to as pre-launch inventory. The Company’s policy is to expense pre-launch inventory as research and development costs, as incurred, until the drug candidate receives marketing authorization. As a result of the policy, while marketing authorization may have been received by the end of a reporting period, any inventories produced prior to such authorization are expensed. If marketing authorization is received and previously expensed pre-launch inventory is sold, such sales may contribute up to a 100% margin to the Company’s operating results. Pre-launch inventory costs include cost of work in process materials and finished drug products.
	Financial Instruments
	The carrying amounts of cash and cash equivalents, short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. A majority of the Company’s long-term obligations consist of variable rate debt and their carrying value approximates fair value. Their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. However, the Company has one fixed-rate, long-term mortgage for which the carrying value differs from the fair value and is not remeasured on a recurring basis (see Note 13).
	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash, money market funds, certificates of deposit and highly liquid investments purchased with original maturities of three months or less.
	Restricted Cash and Restricted Short-Term Investments
	Restricted cash and restricted short-term investments as of December 31, 2014 and 2013 included $1.5 million and $1.3 million, respectively, in certificates of deposit, which is the collateral required for the Company to qualify for workers’ compensation self-insurance and is available to meet the Company’s workers’ compensation obligations on a current basis, as needed. These funds are classified as current assets. The Company’s short-term investments are classified as held- to-maturity and consist of certificates of deposit purchased with maturities greater than three months but mature within one year of the date of purchase. The estimated fair value of each investment approximates its amortized cost.
	Allowance for Doubtful Accounts Receivable
	The Company evaluates the collectability of accounts receivable based on a combination of factors. When the Company is aware of circumstances that may impair a customer’s ability to pay subsequent to the original sale, the Company will record a specific allowance to reduce the amounts due to the amount the Company reasonably believes will be collected. For all other customers, the Company recognizes an allowance for doubtful accounts based on factors that include the length of time the receivables are past due, industry and geographic concentrations, the current business environment and historical collection experience.
	Inventories
	Inventories are stated at the lower of cost or market, using the first-in, first-out method. Provisions are made for slow-moving, unsellable, or obsolete items. Inventories consist of currently marketed products and products manufactured under contract.
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost or, in the case of assets acquired in a business combination, at fair value on the purchase date. Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the related assets as follows:
	Buildings (years)	20	-	31
	Machinery and equipment (years)	2	-	12
	Furniture and fixtures (years)	3	-	7
	Automobiles (years)	4	-	5
	Leasehold improvements	Lesser of remaining lease term or useful life
	Goodwill and Intangible Assets
	Intangible assets with finite lives are amortized over the period the asset is expected to contribute directly or indirectly to the future cash flows of the Company. Product rights are amortized over their estimated useful lives ranging from five to 15 years on a straight-line basis since their projected revenues are expected to be consistent each year. Patents and trademarks are amortized on a straight-line basis over their estimated useful lives, generally ranging from 10 to 20 years. Land-use rights are amortized on a straight-line basis over their useful lives, generally ranging from 37 to 50 years. In accordance with the Company’s accounting policy, the Company tests all intangible assets on an annual basis and between annual tests whenever there is an indication of impairment.
	Impairment of Long-Lived Assets
	The Company reviews long-lived assets and definite-lived intangibles for impairment in the fourth quarter of each year or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets (assets to be held and used) or fair value less cost to sell (assets to be disposed of). The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized.
	Deferred Income Taxes
	The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. The Company has adopted the with-and-without methodology for determining when excess tax benefits from the exercise of share-based awards are realized. Under the with-and-without methodology, current year operating loss deductions and prior-year operating loss carryforwards are deemed to be utilized prior to the utilization of current-year excess tax benefits from share-based awards.
	Self-Insured Claims
	The Company is primarily self-insured, up to certain limits, for workers’ compensation claims. The Company has purchased stop-loss insurance, which will reimburse the Company for individual claims in excess of $350,000 annually or aggregate claims exceeding $1.9 million annually. Operations are charged with the cost of claims reported and an estimate of claims incurred but not reported. A liability for unpaid claims and the associated claim expenses, including incurred but not reported losses, is actuarially determined and reflected in accrued liabilities in the accompanying consolidated balance sheets. Total expense under the program was approximately $1.0 million, $0.8 million, and $1.2 million, for the years ended December 31, 2014, 2013 and 2012, respectively. The self-insured claims liability was $2.2 million and $2.0 million at December 31, 2014 and 2013, respectively. The determination of such claims and expenses and the appropriateness of the related liability is reviewed periodically and updated, as necessary. Changes in estimates are recorded in the period identified.
	Correction of an Immaterial Error
	During the fourth quarter of 2014, the Company identified an immaterial error in the Company’s previously reported consolidated financial statements primarily pertaining to the year ended December 31, 2013 as the result of not capitalizing interest expense on certain foreign construction projects during the year. The Company corrected the immaterial error in the fourth quarter of 2014, resulting in a decrease to net loss by $0.3 million, which has no impact to the Company’s basic and diluted loss per share for the year ended December 31, 2014. Based on management's evaluation of the materiality of the error from a qualitative and quantitative perspective as required by authoritative guidance, the Company concluded that correcting the error had no material impact on any of the Company's previously issued interim financial statements and had no effect on the trend of financial results.
	Business Combinations
	Business combinations are accounted for in accordance with Accounting Standards Codification, or ASC 805, Business Combinations, using the acquisition method of accounting. The acquisition method of accounting requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received.
	Acquisition-related costs are costs the Company incurs to effect a business combination. The Company accounts for acquisition-related costs as expenses in the periods in which the costs are incurred.
	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board, or FASB, issued an Accounting Standard Update to the accounting guidance to address the diversity in practice related to the financial statement presentation of unrecognized tax benefits as either a reduction of a deferred tax asset or a liability when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.
	In April 2014, the FASB issued an accounting standards update that raises the threshold for disposals to qualify as discontinued operations and allows companies to have significant continuing involvement with and continuing cash flows from or to the discontinued operation. It also requires additional disclosures for discontinued operations and new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation. This guidance will be effective for fiscal years beginning after December 15, 2014, which will be the Company's fiscal year 2015, with early adoption permitted. The Company does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.
	In May 2014, the FASB issued an accounting standards update that creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and will be effective for fiscal years beginning after December 15, 2016, which will be the Company's fiscal year 2017. The Company has not yet evaluated the potential impact of adopting the guidance on the Company's consolidated financial statements.
	In June 2014, the FASB issued an accounting standards update that requires a performance target that affects vesting of a share-based payment award and that could be achieved after the requisite service period to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized over the required service period, if it is probable that the performance target will be achieved. This guidance will be effective for fiscal years beginning after December 15, 2015, which will be the Company's fiscal year 2016, with early adoption permitted. The Company does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.
	In August 2014, the FASB issued an accounting standards update that will require management to evaluate if there is substantial doubt about the Company’s ability to continue as a going concern and, if so, to disclose this in both interim and annual reporting periods.  This guidance will become effective for the Company’s annual filing for the period ending December 31, 2016 and interim periods thereafter, and allows for early adoption.  The Company does not expect the adoption of the guidance will have a material impact on the Company’s consolidated financial statements.

Note_3_Business_Acquisition

Note 3 - Business Acquisition	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3.  Business Acquisition
	Acquisition of Merck’s API Manufacturing Business
	On April 30, 2014, the Company completed the acquisition of Merck Sharpe & Dohme’s API manufacturing business in Éragny-sur-Epte, France, or the Merck API Transaction, which manufactures porcine insulin API and recombinant human insulin API. The purchase price of the transaction totaled €24.8 million, or $34.4 million on April 30, 2014, subject to certain customary post-closing adjustments and currency exchange fluctuations. The terms of the purchase include multiple payments over four years as follows (see Note 13):
		Euros			U.S.
					Dollars
		(in thousands)
	At Closing, April 2014	€	13,252		$	18,352
	Dec-14		4,899			5,989
	Dec-15		3,186			3,873
	Dec-16		3,186			3,873
	Dec-17		500			607
		€	25,023		$	32,694
	In order to facilitate the acquisition, the Company established a subsidiary in France, AFP. The Company will continue the current site manufacturing activities, which consist of the manufacturing of porcine insulin API and recombinant human insulin API. As part of the transaction, the Company has entered into various additional agreements, including various supply agreements, as well as the assignment and licensing of patents under which Merck was operating at this facility. In addition, certain existing customer agreements have been assigned to AFP.
	The transaction was accounted for as a business combination in accordance to ASC 805. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:
		Fair Value
		Euros			U.S.
					Dollars
		(in thousands)
	Inventory	€	15,565		$	21,554
	Real property		4,800			6,647
	Machinery & equipment		6,800			9,417
	Intangibles		80			111
	Goodwill		3,155			4,369
	Total assets acquired	€	30,400		$	42,098
	Accrued liabilities	€	2,425		$	3,358
	Deferred tax liabilities		3,155			4,369
	Total liabilities assumed		5,580			7,727
	Total fair value of consideration transferred	€	24,820		$	34,371
	The Company’s accounting for this acquisition is preliminary.  The fair value estimates for the assets acquired and liabilities assumed were based upon preliminary calculations and valuations, and the Company’s estimates and assumptions are subject to change as the Company obtains additional information for its estimates during the measurement period (up to one year from the acquisition date).  During the year ended December 31, 2014, the Company received updated information regarding its deferred tax liability and related goodwill recorded as of the acquisition date.  While finalizing acquisition accounting, the Company recorded a measurement period adjustment which impacted goodwill and deferred tax liability by €3.2 million, or $4.4 million and €3.2 million, or $4.4 million, respectively during the year ended December 31, 2014.  The operations of the acquired business have been included in the Company’s consolidated financial statements commencing on the acquisition date. The results of operations for this acquisition have not been separately presented because this acquisition is not material to the Company’s consolidated results of operations.
	The following unaudited pro forma financial information for the year ended December 31, 2014 and 2013 gives effect to the transaction as if it had occurred on January 1, 2013.  Such unaudited pro forma information is based on historical financial information prior to the transaction as well as actual results subsequent to the acquisition with respect to the transaction and does not reflect estimated operational and administrative cost savings, or synergies, for the periods prior to the transaction that management of the combined company estimates may be achieved as a result of the transaction.  The unaudited pro forma information primarily reflects the additional depreciation related to the fair value adjustment to property, plant and equipment acquired, valuation step up related to the fair value of inventory and additional interest expense associated with the financing obtained by the Company in connection with the acquisition.
		Year Ended
		December 31,
		2014			2013
		(in thousands,
		except per share data)
	Net revenues	$	212,745		$	243,786
	Net income (loss)		(11,928	)		12,969
	Diluted net income (loss) per share	$	(0.28	)	$	0.33
	Acquisition Loan with Cathay Bank
	On April 22, 2014, in conjunction with the Merck API Transaction, the Company entered into a secured term loan with Cathay Bank as lender. The principal amount of the loan is $21.9 million and bears a variable interest rate at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 4.00%. Beginning on June 1, 2014 and through the maturity date, April 22, 2019, the Company must make monthly payments of principal and interest based on the then outstanding amount of the loan amortized over a 120-month period. On April 22, 2019, all amounts outstanding under the loan become due and payable, which would be approximately $12.0 million based upon an interest rate of 4.00%. The loan is secured by 65% of the issued and outstanding shares of stock in AFP and certain assets of the Company, including accounts receivable, inventory, certain investment property, goods, deposit accounts, and general intangibles but not including the Company’s equipment and real property.
	The loan includes customary restrictions on, among other things, the Company’s ability to incur additional indebtedness, pay dividends in cash or make other distributions in cash, make certain investments, create liens, sell assets, and make loans. The loan also includes customary events of defaults, the occurrence and continuation of any of which provide Cathay Bank the right to exercise remedies against the Company and the collateral securing the loan. These events of default include, among other things, the Company’s failure to pay any amounts due under the loan, the Company’s insolvency, the occurrence of any default under certain other indebtedness or material agreements, and a final judgment against the Company that is not discharged in 30 days.

Note_4_Revenue_Recognition

Note 4 - Revenue Recognition	12 Months Ended
	Dec. 31, 2014
Revenue Recognition Disclosure [Abstract]
Revenue Recognition Disclosure [Text Block]	4.  Revenue Recognition
	Generally, revenue is recognized at the time of product delivery to the Company’s customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements. The Company also records profit-sharing revenue stemming from a distribution agreement with Actavis, Inc., or Actavis (see Note 17). Profit-sharing revenue is recognized at the time Actavis sells the products to its customers. Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers, after the customer has accepted test samples of the products to be shipped.
	The Company does not recognize product revenue unless the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) transfer of title has occurred, (iii) the price to the customer is fixed or determinable, and (iv) collection is reasonably assured. Furthermore, the Company does not recognize revenue until all customer acceptance requirements have been met. The Company estimates and records reductions to revenue for discounts, product returns, and pricing adjustments, such as wholesaler chargebacks, in the same period that the related revenue is recorded.
	The Company’s accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit. The Company does not have any revenue arrangements with multiple deliverables.
	Provision for Wholesaler Chargebacks
	The provision for chargebacks is a significant estimate used in the recognition of revenue. As part of its sales terms with wholesale customers, the Company agrees to reimburse wholesalers for differences between the gross sales prices at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company’s various contractual arrangements with third parties such as hospitals and group purchasing organizations. The Company estimates chargebacks at the time of sale to wholesalers based on wholesaler inventory stocking levels, historic chargeback rates, and current contract pricing.
	The provision for chargebacks is reflected in net revenues and a reduction to accounts receivables.  The following table is an analysis of the chargeback provision:
		Year Ended December 31,
		2014			2013
		(in thousands)
	Beginning balance	$	18,104			$	11,898
	Provision related to sales made in the current period		156,235				213,075
	Credits issued to third parties		(162,467	)			(206,869	)
	Ending balance	$	11,872			$	18,104
	Changes in chargeback provision from period to period are primarily dependent on the Company’s sales to its wholesalers, the level of inventory held by the wholesalers’, and on the wholesaler customer mix. The approach that the Company uses to estimate chargebacks has been consistently applied for all periods presented. Variations in estimates have been historically small. The Company continually monitors the provision for chargebacks and makes adjustments when it believes that the actual chargebacks may differ from the estimates. The settlement of chargebacks generally occurs within 30 days after the sale to wholesalers.
	Accrual for Product Returns
	The Company offers most customers the right to return qualified excess or expired inventory for partial credit; however, products sold to Actavis are non-returnable. The Company’s product returns primarily consist of the returns of expired products from sales made in prior periods. Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for estimated returns. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms. The Company also assesses other factors that could affect product returns including market conditions, product obsolescence, and the introduction of new competition. Although these factors do not normally give the Company’s customers the right to return products outside of the regular return policy, the Company realizes that such factors could ultimately lead to increased returns. The Company analyzes these situations on a case-by-case basis and makes adjustments to the product return reserve as appropriate.
	The provision for product returns is reflected in net revenues. The following table is an analysis of product return liability:
		Year Ended December 31,
		2014			2013
		(in thousands)
	Beginning balance	$	4,592			$	2,673
	Provision for product returns		(714	)			2,711
	Credits issued to third parties		(1,470	)			(792	)
	Ending balance	$	2,408			$	4,592
	For the years ended December 31, 2014 and 2013, the Company’s aggregate product return rate was 1.1% and 1.4% of qualified sales, respectively.

Note_5_Income_Loss_Per_Share

Note 5 - Income (Loss) Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	5.  Income (Loss) per Share
	Basic income (loss) per share is calculated based upon the weighted-average number of common shares outstanding during the period and contingently issuable shares such as fully vested deferred stock units, or DSUs, as of the date all necessary conditions for issuance have been met. Diluted income per share gives effect to all potential dilutive common shares outstanding during the period, such as stock options and nonvested DSUs.
	As the Company reported a net loss for the year ended December 31, 2014, the diluted net loss per share, as reported, is equal to the basic net loss per share since the effect of the assumed exercise of stock options and conversion of nonvested DSUs is anti-dilutive. Total stock options and nonvested DSUs excluded from the year ended December 31, 2014 net loss per share were 11,371,891 and 503,010, respectively.
	For the year ended December 31, 2013, options to purchase 7,124,091 shares of common stock with a weighted-average exercise price of $17.62 per share, respectively, were excluded in the computation of diluted net income per share because the effect from the assumed exercise of these options would be anti-dilutive.
	For the year ended December 31, 2012, options to purchase 5,235,278 shares of common stock with a weighted-average exercise price of $22.09 per share, respectively, were excluded in the computation of diluted net income per share because the effect from the assumed exercise of these options would be anti-dilutive.
	The following table provides the calculation of basic and diluted net income (loss) per common share for each of the periods presented:
		Year Ended December 31,
		2014			2013		2012
		(in thousands, except per share data)
	Basic and dilutive numerator:
	Net income (loss)	$	(10,699	)	$	11,862	$	18,094
	Denominator:
	Common shares outstanding		41,957			38,705		38,578
	Contingently issuable shares - vested DSUs		—			7		2
	Weighted-average common shares outstanding—basic		41,957			38,712		38,580
	Net effect of dilutive securities:
	Stock options		—			104		241
	Contingently issuable shares – nonvested DSUs		—			67		119
	Weighted-average common shares outstanding—diluted		41,957			38,883		38,940
	Net income (loss) per common share—basic	$	(0.25	)	$	0.31	$	0.47
	Net income (loss) per common share—diluted	$	(0.25	)	$	0.31	$	0.46

Note_6_Segment_Reporting

Note 6 - Segment Reporting	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	6.  Segment Reporting
	The Company’s business is the development, manufacture, and marketing of pharmaceutical products. On April 30, 2014, the Company established AFP and as a result, during the quarter ended September 30, 2014, the Company changed the structure of its reportable segments, establishing two reporting segments that each report to the Chief Operating Decision Maker, or CODM, as defined in ASC Topic 280, Segment Reporting.  The Company’s performance will be assessed and resources will be allocated by the CODM based on the following two reportable segments:
	-	Finished pharmaceutical products
	-	Active pharmaceutical ingredients, or API
	The finished pharmaceutical products segment currently manufactures, markets and distributes enoxaparin, Cortrosyn®, naloxone, lidocaine jelly, as well as, various other critical and non-critical care drugs.  The API segment currently manufactures and distributes recombinant human insulin and porcine insulin.
	Selected financial information by reporting segment is presented below:
			Year Ended December 31,
			2014				2013				2012
			(in thousands)
	Net revenues:
	Finished pharmaceutical products		$	198,480			$	229,681			$	204,323
	API			11,981				—				—
	Total net revenues			210,461				229,681				204,323
	Gross profit (loss):
	Finished pharmaceutical products			52,724				86,956				90,303
	API			(1,468	)			—				—
	Total gross profit			51,256				86,956				90,303
	Operating expenses			69,239				69,466				64,906
	Income (loss) from operations			(17,983	)			17,490				25,397
	Non-operating income (expenses)			(165	)			(263	)			481
	Income (loss) before income taxes		$	(18,148	)		$	17,227			$	25,878
	The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis.  The Company does not identify total assets by segment for internal purposes, as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets.
	Net revenues and carrying values of long-lived assets of enterprises by geographic regions are as follows:
			Net Revenue										Long-Lived Assets
			Year Ended December 31,										December 31,
			2014			2013				2012			2014			2013
			(in thousands)
	U.S.		$	198,480			$	229,681			$	204,323		$	102,313		$	99,398
	China			—				—				—			22,170			17,221
	France			11,981				—				—			13,806			—
	Total		$	210,461			$	229,681			$	204,323		$	138,289		$	116,619

Note_7_Customer_and_Supplier_C

Note 7 - Customer and Supplier Concentration	12 Months Ended
	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	7.  Customer and Supplier Concentration
	Customer Concentrations
	Three large wholesale drug distributors, AmerisourceBergen Corporation, or AmerisourceBergen, Cardinal Health, Inc. or Cardinal, and McKesson Corporation, or McKesson, are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. Actavis, Inc. has exclusive marketing rights of the Company’s enoxaparin product to the U.S. retail pharmacy market. MannKind Corporation began buying RHI API from the Company in December 2014. The Company considers these five customers to be its major customers, as each individually and they collectively represented a significant percentage of the Company’s net revenue for the years ended December 31, 2014, 2013, and 2012, and accounts receivable as of December 31, 2014 and 2013.  The following table provides accounts receivable and net revenues information for these major customers:
		% of Total Accounts						% of Net
		Receivable						Revenue
		December 31,						Year Ended December 31,
		2014			2013			2014			2013			2012
	Actavis, Inc.		18	%		44	%		30	%		35	%		35	%
	AmerisourceBergen		5	%		11	%		15	%		15	%		14	%
	Cardinal Health		15	%		7	%		14	%		13	%		13	%
	MannKind Corporation		21	%		—			2	%		—			—
	McKesson		13	%		13	%		22	%		26	%		27	%
	Supplier Concentrations
	The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent U.S. Food and Drug Administration, or FDA, requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial period of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture and market its products, it could have a materially adverse effect on the Company’s business, financial condition, and results of operations.

Note_8_Fair_Value_Measurements

Note 8 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	8.  Fair Value Measurements
	The accounting standards of the Financial Accounting Standards Board, or FASB, define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal or most advantageous market for the asset or liability at the measurement date (an exit price). These standards also establish a hierarchy that prioritizes observable and unobservable inputs used in measuring fair value of an asset or liability, as described below:
	·	Level 1 – Inputs to measure fair value are based on quoted prices (unadjusted) in active markets on identical assets or liabilities;
	·	Level 2 – Inputs to measure fair value are based on the following: a) quoted prices in active markets on similar assets or liabilities, b) quoted prices for identical or similar instruments in inactive markets, or c) observable (other than quoted prices) or collaborated observable market data used in a pricing model from which the fair value is derived; and
	·	Level 3 – Inputs to measure fair value are unobservable and the assets or liabilities have little, if any, market activity; these inputs reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities based on best information available in the circumstances.
	The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
	The Company classifies its cash equivalents and short-term investments as Level 1 assets, as they are valued on a recurring basis using quoted market prices with no valuation adjustments applied. The Company does not hold any Level 2 or Level 3 instruments that are measured for fair value on a recurring basis.
	The fair values of the Company’s financial assets and liabilities measured on a recurring basis, as of December 31, 2014 and 2013, are as follows:
			Total		Quoted Prices in		Significant Other		Significant
					Active Markets		Observable Inputs		Unobservable Inputs
					for Identical		(Level 2)		(Level 3)
					Assets
					(Level 1)
			(in thousands)
	Cash equivalents:
	Money market accounts		$	42,994	$	42,994	$	—	$	—
	Restricted short-term investments:
	Certificates of deposit			1,495		1,495		—		—
	Fair value measurement as of December 31, 2014		$	44,489	$	44,489	$	—	$	—
	Cash equivalents:
	Money market accounts		$	41,183	$	41,183	$	—	$	—
	Restricted short-term investments:
	Certificates of deposit			1,325		1,325		—		—
	Fair value measurement as of December 31, 2013		$	42,508	$	42,508	$	—	$	—
	The fair value of the Company’s cash equivalents includes money market funds and certificates of deposit with maturities of one year or less. Short-term investments consist of certificate of deposit accounts that expire within 12 months for which market prices are readily available. The restrictions placed on the certificate of deposit accounts have a negligible effect on the fair value of these financial assets; these funds are restricted to meet the Company’s obligation for workers’ compensation claims.
	The Company adopted the required fair value measurements and disclosures provisions related to nonfinancial assets and liabilities. These assets and liabilities are not measured at fair value on a recurring basis but are subject to fair value adjustments in certain circumstances. These items primarily include long-lived assets, goodwill, and intangible assets for which the fair value of assets is determined as part of the related impairment test. As of December 31, 2014 and 2013, there were no significant adjustments to fair value for nonfinancial assets or liabilities.

Note_9_Goodwill_and_Intangible

Note 9 - Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	9. Goodwill and Intangible Assets
	Intangible assets include product rights, trademarks, patents, land-use rights, and goodwill. The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification:
		Weighted-Average Life (Years)				Original Cost		Accumulated Amortization		Net Book Value
						(in thousands)
	Definite-lived intangible assets
	Product rights		12			$	27,134	$	20,896	$	6,238
	Patents		10				293		78		215
	Trademarks		11				19		15		4
	Land-use rights		39				2,540		221		2,319
	Other intangible assets		1				505		505		—
	Subtotal		12				30,491		21,715		8,776
	Indefinite-lived intangible assets
	Trademark		*				29,225		—		29,225
	Goodwill
	Finished pharmaceutical products		*				280		—		280
	API		*				4,187		—		4,187
	AFP customers		*				97		—		97
	Subtotal		*				33,789		—		33,789
	As of December 31, 2014		*			$	64,280	$	21,715	$	42,565
		Weighted-Average Life (Years)				Original Cost		Accumulated Amortization		Net Book Value
						(in thousands)
	Definite-lived intangible assets
	Product rights		12			$	27,134	$	19,114	$	8,020
	Patents		10				298		50		248
	Trademarks		11				19		13		6
	Land-use rights		39				2,540		156		2,384
	Other intangible assets		1				505		505		—
	Subtotal		11				30,496		19,838		10,658
	Indefinite-lived intangible assets
	Trademark		*				29,225		—		29,225
	Goodwill
	Finished pharmaceutical products		*				280		—		280
	API		*				—		—		—
	Subtotal		*				29,505		—		29,505
	As of December 31, 2013		*			$	60,001	$	19,838	$	40,163
	* Intangible assets with indefinite lives have an undeterminable average life.
	Goodwill acquired during the year ended December 31, 2014 is wholly related to the Merck API Transaction (see Note 3).
	Goodwill
	The Changes in the carrying amounts of goodwill were as follow:
		December 31,
		2014			2013
		(in thousands)
	Beginning balance	$	280			$	280
	Goodwill related to acquisition of business		4,369				—
	Currency translation and other adjustments		(182	)			—
	Ending Balance	$	4,467			$	280
	Primatene® Mist Trademark
	In January 2009, the Company acquired the exclusive rights to the trademark, domain name, website and domestic marketing, distribution and selling rights related to Primatene® Mist, an over-the-counter bronchodilator product, for a total consideration of $29.2 million, which is the carrying value as of December 31, 2014.
	In determining the useful life of the trademark, the Company considered the following: the expected use of the intangible; the longevity of the brand; the legal, regulatory and contractual provisions that affect their maximum useful life; the Company’s ability to renew or extend the asset’s legal or contractual life without substantial costs; effects of the regulatory environment; expected changes in distribution channels; maintenance expenditures required to obtain the expected future cash flows from the asset; and considerations for obsolescence, demand, competition and other economic factors.
	As a result of environmental concerns about chlorofluorocarbons, or CFCs, the FDA issued a final ruling on January 16, 2009 that required the CFC formulation of its Primatene® Mist product to be phased out by December 31, 2011. The former formulation of Primatene® Mist contained CFCs as a propellant; however, the Company intends to use the trademark for a future version of Primatene® Mist that utilizes hydrofluoroalkane, or HFA, as a propellant.
	In 2013, the Company filed a new drug application, or NDA, for Primatene® Mist HFA and received a Prescription Drug User Fee Act date set for May 2014.  In May 2014, the Company received a complete response letter, or CRL, from the FDA, which requires additional non-clinical information, label revisions and follow-up studies (label comprehension, behavioral and actual use) to assess consumers’ ability to use the device correctly to support approval of the product in the over-the-counter setting. Additionally the CRL noted current Good Manufacturing Practices, or cGMP, deficiencies in a recent inspection of the Company’s API supplier’s manufacturing facility, which produces epinephrine, and indicated that the Company’s NDA could not be approved until these issues were resolved. Subsequent to the receipt of the CRL, the supplier notified the Company that the cGMP deficiencies were satisfactorily resolved.  Accordingly, the Company believes this condition for approval has been satisfied.  The Company met with the FDA in October 2014 to discuss preliminary data results and to clarify the FDA requirements for further studies. The Company is in the process of generating the remaining data required by the CRL and will submit an NDA Amendment that it believes will address the FDA’s concerns. However, there can be no guarantee that any amendment to the Company’s NDA will result in timely approval of the product or approval at all.
	Based on the Company’s filed version of Primatene® Mist HFA, the Company’s plan to submit an NDA amendment to address the FDA’s concerns, the long history of the Primatene® Mist trademark (marketed since 1963) and the Company’s perpetual rights to the trademark, the Company has determined that the trademark has an indefinite useful life. If the HFA version is approved by the FDA, it will be marketed under the same trade name; therefore, an impairment charge would not be required.
	Amortization
	Included in cost of revenues for the years ended December 31, 2014, 2013 and 2012 is product rights amortization expense of $1.8 million each year, primarily related to Cortrosyn®.
	As of December 31, 2014, the expected amortization expense for all amortizable intangible assets during the next five fiscal years ended December 31 and thereafter is as follows:
		(in thousands)
	2015	$	1,878
	2016		1,878
	2017		1,877
	2018		986
	2019		95
	Thereafter		2,062
	Total amortizable intangible assets		8,776
	Indefinite-lived intangibles		33,789
Total intangibles (net of accumulated amortization)	$	42,565

Note_10_Inventories

Note 10 - Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	10. Inventories
	Inventories are stated at the lower of cost or market, using the first-in, first-out method. Provisions are made for slow-moving, unsellable or obsolete items. Inventories consist of the following:
		December 31,
		2014			2013
		(in thousands)
	Raw materials and supplies	$	41,996		$	34,470
	Work in process		16,221			14,698
	Finished goods		24,755			26,501
	Total inventory		82,972			75,669
	Less reserve for excess and obsolete inventories		(640	)		(5,753	)
	Total inventory, net	$	82,332		$	69,916

Note_11_Property_Plant_and_Equ

Note 11 - Property, Plant, and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	11.  Property, Plant, and Equipment
	Property, plant, and equipment consist of the following:
		December 31,
		2014			2013
		(in thousands)
	Building	$	67,760		$	58,898
	Leasehold improvements		23,960			23,834
	Land		7,020			5,805
	Machinery and equipment		104,819			93,617
	Furniture, fixtures, and automobiles		12,213			9,355
	Construction in progress		25,068			15,685
	Total property, plant, and equipment		240,840			207,194
	Less accumulated depreciation and amortization		(102,551	)		(90,575	)
	Total property, plant, and equipment, net	$	138,289		$	116,619
	The Company incurred depreciation expense of $12.5 million, $11.2 million, and $9.7 million for the years ended December 31, 2014, 2013, and 2012, respectively.
	Interest expense capitalized was approximately $1.2 million, $0.1 million, and $0.3 million, for the years ended December 31, 2014, 2013, and 2012, respectively.  The interest expense capitalized is primarily related to certain foreign construction projects during the year.
	As of December 31, 2014 and 2013, the Company had $3.4 million and $3.4 million, respectively, in capitalized manufacturing equipment that is intended to be used specifically for the manufacture of Primatene® Mist HFA. The Company will continue to monitor developments with the FDA as it relates to its Primatene® Mist HFA in determining if there is an impairment of these related fixed assets (see Note 9).

Note_12_Impairment_of_LongLive

Note 12 - Impairment of Long-Lived Assets	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Asset Impairment Charges [Text Block]	12. Impairment of Long-Lived Assets
	All of the Company’s impairments relate primarily to the write-off of certain manufacturing equipment related to abandoned projects. For the years ended December 31, 2014, 2013 and 2012, the Company recorded an impairment loss of $0.4 million, $0.1 million, and $2.1 million, respectively in the Finished Pharmaceutical Product segment. The $2.1 million impairment write-off in 2012 is primarily related to equipment for a production project that was suspended.

Note_13_Debt

Note 13 - Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	13. Debt
	Debt consists of the following:
		December 31,
		2014		2013
		(in thousands)
	Loans with East West Bank
	Mortgage payable due January 2016	$	3,887	$	4,041
	Mortgage payable due September 2016		2,289		2,364
	Equipment loan paid off November 2014		—		783
	Line of credit facility due March 2016		—		—
	Equipment loan due April 2017		2,923		4,103
	Line of credit facility due January 2019		—		—
	Loans with Cathay Bank
	Mortgage payable due April 2021		4,549		4,624
	Revolving line of credit due May 2016		—		15,000
	Acquisition loan due April 2019		20,870		—
	Payment obligation to Merck		8,160		—
	Equipment under Capital Leases		1,022		1,258
	Total debt and capital leases		43,700		32,173
	Less current portion of long-term debt and capital leases		7,594		22,104
	Long-term debt, net of current portion and capital leases	$	36,106	$	10,069
	Loans with East West Bank
	Mortgage Payable—Due January 2016
	In December 2010, the Company refinanced an existing mortgage term loan, which had a principal balance outstanding of $4.5 million at December 31, 2010. The loan is payable in monthly installments with a final balloon payment of $3.8 million. The loan is secured by one of the buildings at the Company’s Rancho Cucamonga, California, headquarters complex, as well as one of its buildings at its Chino, California, complex. The loan bears a variable interest rate at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 5.00%, and matures in January 2016.
	Mortgage Payable—Due September 2016
	In September 2006, the Company entered into a mortgage term loan in the principal amount of $2.8 million, which matures in September 2016. The loan is payable in monthly installments with a final balloon payment of $2.2 million plus interest. The loan is secured by one of the buildings at the Company’s Rancho Cucamonga, California, headquarters complex. The variable interest rate is equal to the three-month LIBOR plus 2.50%.
	Equipment Loan—Paid off November 2014
	In May 2009, the Company entered into an $8.0 million revolving credit facility. In November 2010, the Company converted the outstanding principal balance of $3.2 million into an equipment loan. Borrowings under the facility were secured by equipment purchased with debt proceeds. The facility bore interest at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 5.00%.  In November 2014, the Company repaid all outstanding amounts due under this facility.
	Line of Credit Facility—Due March 2016
	In March 2012, the Company entered into a $10.0 million line of credit facility. Borrowings under the facility are secured by inventory and accounts receivable.  Borrowings under the facility bear interest at the prime rate as published by The Wall Street Journal. This facility was to mature in July 2014.  In April 2014, the Company extended the maturity date to March 2016.  As of December 31, 2014, the Company did not have any amounts outstanding under this facility.
	Equipment Loan—Due April 2017
	In March 2012, the Company entered into an $8.0 million revolving credit facility. In March 2013, the Company, converted the outstanding principal balance of $4.9 million into an equipment loan. Borrowings under the facility are secured by equipment purchased with debt proceeds. Borrowings under the facility bear interest at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 3.50%. This facility matures in April 2017.
	Line of Credit Facility—Due January 2019
	In July 2013, the Company entered into an $8.0 million line of credit facility.  Borrowings under the facility were secured by equipment. The facility bore interest at the prime rate as published in The Wall Street Journal plus 0.25% and was to mature in January 2019.  As of December 31, 2014, the Company did not have any amounts outstanding under this facility.
	In January 2015, the Company drew down $6.2 million from the line of credit facility. Subsequently, the facility was then converted in an equipment loan with an outstanding principal balance of $6.2 million. Borrowings under the facility are secured by equipment purchased with the debt proceeds.  The Company entered into a fixed interest rate swap contract on this facility to exchange the floating rate for a fixed interest payment over the life of the facility without the exchange of the underlying notional debt amount. The facility bears interest at a fixed rate of 4.48% and matures in January 2019.
	Loans with Cathay Bank
	Mortgage Payable—Due April 2021
	In March 2007, the Company entered into a mortgage term loan in the principal amount of $5.3 million, which matured in March 2014.  In April 2014, the Company refinanced the mortgage term loan, which had a principal balance outstanding of $4.6 million.  The loan is payable in monthly installments of $28.1 thousand with a final balloon payment of $3.9 million.  The loan is secured by the building at the Company’s Canton, Massachusetts location and bears interest at a fixed rate of 5.42% and matures in April 2021.  As of December 31, 2014, the loan had a fair value of $4.8 million, compared to a book value of $4.5 million. The fair value of the loan was determined by using the interest rate associated with the Company’s mortgage loans with similar terms and collateral that has variable interest rates. The fair value of debt obligations is not re-measured on a recurring basis and the variable interest rate is deemed to be a Level 2 input for measuring fair value.
	Revolving Line of Credit—Due May 2016
	In April 2012, the Company entered into a $20.0 million revolving line of credit facility.  Borrowings under the facility are secured by inventory, accounts receivables, and intangibles held by the Company.  The facility bears interest at the prime rate as published by The Wall Street Journal with a minimum interest rate of 4.00%.  This revolving line of credit was to mature in May 2014.  In April 2014, the Company modified the facility to extend the maturity date to May 2016.  As of December 31, 2014, the Company did not have any amounts outstanding under this facility.
	Acquisition Loan—Due April 2019
	On April 22, 2014, in conjunction with the Merck API Transaction, the Company entered into a secured term loan facility. The principal amount of the loan is $21.9 million and bears a variable interest rate at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 4.00%. Beginning on June 1, 2014 and through the maturity date, April 22, 2019, the Company must make monthly payments of principal and interest based on the then outstanding amount of the loan amortized over a 120-month period. On April 22, 2019, all amounts outstanding under the loan become due and payable, which would be approximately $12.0 million based upon an interest rate of 4.00%. The loan is secured by 65% of the issued and outstanding shares of stock in AFP and certain assets of the Company, including accounts receivable, inventory, certain investment property, goods, deposit accounts, and general intangibles but not including the Company’s equipment and real property.
	The loan includes customary restrictions on, among other things, the Company’s ability to incur additional indebtedness, pay dividends in cash or make other distributions in cash, make certain investments, create liens, sell assets, and make loans. The loan also includes customary events of defaults, the occurrence and continuation of any of which provide Cathay Bank the right to exercise remedies against the Company and the collateral securing the loan. These events of default include, among other things, the Company’s failure to pay any amounts due under the loan, the Company’s insolvency, the occurrence of any default under certain other indebtedness or material agreements, and a final judgment against the Company that is not discharged in 30 days.
	Payment Obligation
	Merck—Due December 2017
	On April 30, 2014, in conjunction with the Merck API Transaction, the Company entered into a commitment obligation with Merck, in the principal amount of €11.6 million, or $16.0 million, subject to currency exchange fluctuations.  The terms of the purchase price include annual payments over four years and bear a fixed interest rate of 3.00%. The final payment to Merck relating to this obligation is due December 2017.  In December 2014, the Company made a principal payment of €4.9 million, or $6.0 million.
	As of December 31, 2014, the payment obligation had a book value of €6.9 million, or $8.2 million, which approximates fair value.  The fair value of the payment obligation was determined by using the interest rate associated with the Company’s acquisition loan with Cathay Bank that bears a variable interest rate at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 4.00%.  The fair value of the debt obligation is not re-measured on a recurring basis and the variable interest rate is deemed to be a Level 2 input for measuring fair value.
	Covenants
	At December 31, 2014, the Company was not in compliance with two of its financial covenants with Cathay Bank. The first one requiring a fixed charge coverage ratio of 1.2 to 1.0, or greater, and the second one required a minimum debt service coverage ratio of 1.5 to 1.0, or greater. On March 13, 2015, the Company obtained waivers of the debt covenants for the period ending December 31, 2014.  At December 31, 2013, the Company was in compliance with its debt covenants, which include a minimum current ratio, minimum debt service coverage, minimum tangible net worth, and maximum debt-to-effective-tangible-net-worth ratio, computed on a consolidated basis in some instances and on a separate-company basis in others.
	Equipment under Capital Leases
	The Company entered into leases for certain equipment under capital leasing arrangements, which will expire at various times through 2019. The cost of equipment under capital leases was $1.5 million and $1.5 million at December 31, 2014 and 2013, respectively.
	The accumulated amortization of equipment under capital leases was $0.4 million and $0.2 million at December 31, 2014 and 2013, respectively. Amortization of assets recorded under capital leases is included in depreciation and amortization expense in the accompanying consolidated financial statements.
	Long-Term Debt Maturities
	As of December 31, 2014, the principal amounts of long-term debt maturities during each of the next five fiscal years ending December 31 are as follows:
		Debt		Capital Leases		Total
		(in thousands)
	2015	$	7,243	$	403
	2016		12,973		301
	2017		3,131		298
	2018		2,203		126
	2019		13,076		—
	Thereafter		4,052		—
			42,678		1,128
	Less amount representing interest		—		106
	$	42,678	$	1,022	$	43,700

Note_14_Income_Taxes

Note 14 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	14. Income Taxes
	The Company’s income (loss) before income taxes generated from its United States and foreign operations were:
		Year Ended December 31,
		2014			2013			2012
		(in thousands)
	Income (loss) before income taxes:
	United States	$	(12,946	)	$	20,116		$	27,715
	Foreign		(5,202	)		(2,889	)		(1,837	)
	Total income (loss) before taxes	$	(18,148	)	$	17,227		$	25,878
	The Company’s provision (benefit) for income taxes consisted of the following:
		Year Ended December 31,
		2014			2013			2012
		(in thousands)
	Current provision (benefit):
	Federal	$	(131	)	$	3,306		$	(1,304	)
	State		193			541			(2,337	)
	Foreign		1,388			104			94
	Total current provision (benefit)		1,450			3,951			(3,547	)
	Deferred provision (benefit):
	Federal		(4,309	)		2,254			11,817
	State		(1,699	)		227			170
	Foreign		(2,891	)		(1,067	)		(656	)
	Total deferred provision (benefit)		(8,899	)		1,414			11,331
	Total provision (benefit) for income taxes	$	(7,449	)	$	5,365		$	7,784
	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:
		Year Ended December 31,
		2014			2013			2012
	Statutory federal income tax (benefit)		(35.0	%)		35	%		35	%
	State tax expense, net of federal tax benefit		(5.4	)		2.9			(4.7	)
	Foreign income tax		1.8			0.3			0.1
	Qualified production activities deduction		—			(3.3	)		—
	Research and development credits		(6.4	)		(9.9	)		—
	Benefit for uncertain tax position		—			—			(3.0	)
	ISO portion of stock options deductions		4			6.3			4
	Other		—			(0.2	)		(1.3	)
	Effective tax rate (benefit)		(41.0	%)		31.1	%		30.1	%
	Deferred Tax Assets and Liabilities
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the Company’s deferred tax assets and liabilities are as follows:
		December 31,
		2014			2013
		(in thousands)
	Deferred tax assets:
	Net operating loss carryforward	$	7,877		$	933
	State income taxes		270			290
	Inventory capitalization and reserve		6,843			5,800
	Deferred revenue		864			1,151
	Accrued payroll and benefits		1,571			1,465
	Share-based compensation		8,437			6,987
	Research and development credits		9,863			7,751
	Alternative minimum tax		447			406
	Accrued professional fees		568			885
	Product return allowance		1,221			2,092
	Accrued chargebacks		4,792			7,187
	Bad debt reserve		67			57
	Intangibles		3,861			—
	Accrued for workers’ compensation insurance		864			776
	Total deferred tax assets		47,545			35,780
	Deferred tax liabilities:
	Depreciation/amortization		15,649			13,920
	Intangibles		4,753			3,828
	Federal impact of state deferred taxes		2,910			2,397
	Other		937			575
	Total deferred tax liabilities		24,249			20,720
	Valuation Allowance		3,862			—
Net deferred tax assets	$	19,434		$	15,060
Net Operating Loss Carryforwards and Tax Credits
At December 31, 2014, the Company had U.S. federal, California , and other State net operating loss (“NOL”) carryforwards of approximately $15.4 million, $15.5 million, and $1.6 million, respectively. The federal, California and other states loss carryforwards begin to expire in 2034, 2029, and 2030, respectively. The Company also had foreign NOL carryforwards of approximately $2.9 million which can be used annually with certain limitations and have an indefinite carryforward period.
The California and other state NOL carryforwards exclude $15.8 million and $0.1 million, respectively, related to excess tax benefits from share-based awards. When the related tax benefits from these share-based awards are utilized, the tax benefit of these adjustments which will reduce the amount of income taxes payable will be offset against additional paid in capital.
At December 31, 2014, the Company had federal and California research and development tax credit carryforwards of approximately $2.7 million and $7.2 million, respectively. The federal research and development tax credit begins to expire in 2031 unless utilized beforehand. The California research and development tax credit has an indefinite carryforward period. The Company also had a U.S. federal alternative minimum tax credit carryforward of $0.4 million which can be used to offset future regular tax to the extent of the current AMT; the credit has an indefinite carryforward period.
The utilization of the NOL and credit carryforwards and other tax attributes could be subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986 (the “Code”), whereby they could be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period, as defined in the Code.
Valuation Allowance
In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. When making an assessment when to establish a valuation allowance, Management considers sources of taxable income such as income in prior carryback periods, future reversal of existing deferred taxable temporary differences, projected future taxable income, and tax-planning strategies. Based on these assessments, Management believes that the Company’s deferred tax assets will more likely than not be realized in future years, except for the deferred tax asset related to certain intangible assets purchased by AFP in conjunction with the purchase of an API facility in France in April 2014. As a result, in connection with the AFP purchase accounting, the Company recorded a valuation allowance against the intangible deferred tax asset of $4.4 million with an offsetting entry to goodwill.
Undistributed Earnings (Losses) from Foreign Operations
As of December 31, 2014 and 2013, deferred income taxes have not been provided on the accumulated undistributed losses of the Company’s foreign subsidiaries of approximately $10.5 million and $5.0 million, respectively. In addition, it is the Company’s plan not to repatriate future foreign earnings to the U.S.
Uncertain Income Tax Positions
A reconciliation of the beginning and ending balances of unrecognized tax benefits is as follows:
	December 31,
	2014			2013
	(in thousands)
Balance at the beginning of the year	$	4,186		$	3,532
Additions based on tax positions related to the current year		655			766
Deductions based on tax audit settlement		—			(93	)
Deductions based on statute of limitations		(58	)		(19	)
Balance at the end of the year	$	4,783		$	4,186
Included in the balance of unrecognized tax benefits as of December 31, 2014 was $4.3 million that represents the portion that would impact the effective income tax rate if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefit as of December 31, 2014 will decline by $1.9 million in the next 12 months as a result of the expected resolution of a current U.S. state audit.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax provision. For the years ended December 31, 2014 and 2013, the Company recognized accrued interest of approximately $0.1 million and $0.1 million, respectively, related to its uncertain tax position. For the year ended December 31, 2012, the Company recognized a net reduction to its income tax provision of approximately $1.2 million, related to its uncertain tax position. No penalties were required to be accrued on its uncertain tax positions.
The Company and/or one or more of its subsidiaries filed income tax returns in the U.S. federal jurisdiction and various U.S. states and foreign jurisdictions.  As of December 31, 2014, the Company is not subject to U.S. federal, state, and foreign income tax examinations for years before 2006. In August 2011, the California FTB commenced an audit of the Company’s 2007, 2008, and 2009 tax returns; this audit is currently ongoing.  The Company is subject to income tax audit by tax authorities for tax years 2011, 2012 and 2013 for federal and 2007 to 2013 for states.

Note_15_Stockholders_Equity

Note 15 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	15. Stockholders' Equity
	Common and Preferred Stock
	In June 2014, the Company completed an initial public offering in which the Company sold 5,840,000 shares of its common stock, which included 1,200,000 shares of the Company’s common stock pursuant to the underwriters’ exercise of their over-allotment option, at a price to the public of $7.00 per share, resulting in gross proceeds of $40.9 million.  In connection with the offering, the Company paid $6.2 million in underwriting discounts, commissions, and offering costs, resulting in net proceeds of $34.7 million.
	The Company’s Certificate of Incorporation, as amended and restated in June 2014 in connection with the closing of its initial public offering, authorizes the Company to issue 300,000,000 shares of common stock, $0.0001 par value per share, and 20,000,000 shares of preferred stock, $0.0001 par value per share. As of December 31, 2014 and 2013, there were no shares of preferred stock issued or outstanding.
	Equity Plans
	As of December 31, 2014, the Company had two equity plans, the Amended and Restated 2005 Equity Incentive Award Plan, or 2005 Plan, and the 2014 Employee Stock Purchase Plan or ESPP. Prior to the adoption of these plans, the Company granted options pursuant to the 2002 Amended and Restated Stock Option/Stock Issuance Plan and, from 1998 through 2001, the Company’s board of directors granted options to purchase shares of its common stock under the Key Employee Stock Incentive Plan, the 2001 Employee Incentive Plan, the 2000 Employee Incentive Plan and the 1999 Employee Incentive Plan.  Upon termination of the predecessor plans, the shares available for grant at the time of termination, and shares subsequently returned to the plans upon forfeiture or option termination, were transferred to the successor plan in effect at the time of share return.
	The Company issues new shares of common stock upon exercise of stock options.
	Amended and Restated 2005 Equity Incentive Award Plan
	The 2005 Plan provides for the grant of incentive stock options, or ISOs, nonqualified stock options, or NQSOs, restricted stock awards, restricted stock unit awards, stock appreciation rights, or SARs, dividend equivalents and stock payments to our employees, members of the board of directors and consultants. Stock options under the 2005 Plan may be granted with a term of up to ten years and at prices no less than the fair market value of our common stock on the date of grant. To date, stock options granted to existing employees generally vest over three to five years and stock options granted to new employees vest over four years. The 2005 Plan also contains an "evergreen provision" that allows for an annual increase in the number of shares available for issuance on January 1 of each year during the ten-year term of the 2005 Plan, beginning January 1, 2007. The annual increase in the number of shares shall be either 2% of our outstanding shares on the applicable January 1 or a lesser amount determined by our board of directors.
	As of December 31, 2014 the Company reserved an aggregate of 2.3 million shares of common stock for future issuance under the 2005 Plan. In January 2015, an additional 892,936 shares were reserved under the 2005 Plan.
	2014 Employee Stock Purchase Plan
	The Company adopted the ESPP in June 2014 in connection with its initial public offering. The Company’s ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Under the ESPP, the Company may specify offerings with durations of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of its common stock will be purchased for employees participating in the offering. An offering may be terminated under certain circumstances. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or on the date of purchase.
	As of December 31, 2014, the Company had not provided for any offerings under the ESPP and 2,000,000 shares of its common stock remained available for issuance under the ESPP.
	Share Buyback Program
	On November 6, 2014 the Company’s Board of Directors authorized a $10.0 million share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company’s equity compensation programs.
	Purchases are being made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Company’s management and in accordance with the requirements of the Securities and Exchange Commission.  The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.  These repurchased shares are accounted for under the cost method and are included as a component of treasury stock in the Company’s Consolidated Balance Sheets.
	Pursuant to the Company’s share repurchase program, the Company purchased 29,400 shares of its common stock during the year ended December 31, 2014 totaling $0.3 million.
	Share-Based Award Activity and Balances
	The Company accounts for share-based compensation payments in accordance with ASC Topic 718, which require measurement and recognition of compensation expense at fair value for all share-based payment awards made to employees, directors, and non-employees. Under these standards, the fair value of share-based payment awards is estimated at the grant date using an option-pricing model and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of share-based awards and recognizes share-based compensation cost over the vesting period using the straight-line single option method.  Non-vested stock options held by non-employees are revalued using the Company’s estimate of fair value at each balance sheet date.
	Options issued under the Company’s Amended and Restated 2005 Equity Incentive Award Plan, or the 2005 Plan, are generally granted at prices equal to or greater than the fair value of the underlying shares on the date of grant and vest based on continuous service. The options have a contractual term of five to ten years and generally vest over a three- to five-year period. The fair value of each option is amortized into compensation expense on a straight-line basis between the grant date for the option and the vesting date. The awards of restricted common stock such as Deferred Stock Units, or DSUs are valued at fair value on the date of grant. The Company uses the Black-Scholes option pricing model to determine the fair value of share-based awards. The Black-Scholes option pricing model has various inputs such as the estimated common share price, the risk-free interest rate, volatility, expected life and dividend yield, all of which are estimates. The Company also records share-based compensation expense net of expected forfeitures. The change of any of these inputs could significantly impact the determination of the fair value of the Company’s options and thus could significantly impact its results of operations. There are no awards with performance conditions and no awards with market conditions.
	Valuation models and significant assumptions for share-based compensation are as follows:
		▪	Determining Fair Value.  For all equity awards granted after the completion of the Company’s initial public offering, the fair value for its underlying common stock is determined using the closing price on the date of grant as reported on the NASDAQ Global Select Market. The Company uses the Black-Scholes formula to estimate the fair value of our share-based payments using a single option award approach. The application of this valuation model involves assumptions that are judgmental and sensitive in the determination of compensation expense. Key assumptions and estimation methodologies for inputs to the Black-Scholes calculation are developed in accordance with ASC Topic 718. The Company amortizes its share-based compensation expense over the requisite service period, which in most cases is the vesting period of the award.
	For all equity grants granted, the primary factor in the valuation of equity awards was the fair value of the underlying common stock at the time of grant. Since the Company’s common stock was not traded in a public stock market exchange prior to June 25, 2014, the Board of Directors considered numerous factors including recent cash sales of the Company’s common stock to third-party investors, new business and economic developments affecting the Company and independent appraisals, when appropriate, to determine the fair value of the Company’s common stock. Independent appraisal reports were prepared using conventional valuation techniques, such as discounted cash flow analyses and the guideline company method using revenue and earnings multiples for comparable publicly traded companies, and a calculation of total option proceeds, from which a discount factor for lack of marketability was applied. This determination of the fair value of the common stock was performed on a contemporaneous basis. The Board of Directors determined the Company’s common stock fair market value on a quarterly basis and in some cases more frequently when appropriate.
		▪	Expected Volatility.  The Company has limited data regarding company-specific historical or implied volatility of its share price. Consequently, the Company estimates its volatility based on the average of the historical volatilities of peer group companies from publicly available data for sequential periods approximately equal to the expected terms of its option grants. Management considers factors such as stage of life cycle, competitors, size, market capitalization and financial leverage in the selection of similar entities.
		▪	Expected Term.  The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options granted based on the midpoint between the vesting date and the end of the contractual term under the “short-cut” or simplified method permitted by the SEC implementation guidance for “plain vanilla” options. Applying this method, the weighted-average expected term of the Company’s options is approximately five years. The use of the short-cut method is permitted by the SEC beyond December 31, 2007, under certain circumstances, as described in the SEC implementation guidance. The Company will continue to use the short-cut method, as permitted, until we have developed sufficient historical data for employee exercise and post-vesting employment termination behavior after our common stock has been publicly traded for a reasonable period of time.
		▪	Forfeitures.  The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual experience differs from those estimates. For the years ended December 31, 2014, 2013 and 2012, the Company estimated an average overall forfeiture rate of 8%, 8%, and 9%, respectively, based on historical forfeitures since 1998. Forfeiture rates are separately calculated for its (1) directors and officers, (2) management personnel and (3) other employees. Share-based compensation is recorded net of expected forfeitures. The Company will periodically assess the forfeiture rate and the amount of expense recognized based on estimated historical forfeitures as compared to actual forfeitures. Changes in estimates are recorded in the period they are identified.
		▪	Risk-Free Rate.  The risk-free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero-coupon issues with a term approximately equal to the expected life of the option being valued.
		▪	Dividends.  The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of zero.
	Tax benefits resulting from tax deductions in excess of the share-based compensation cost recognized (excess tax benefits) are recorded in the statements of cash flows as financing activities.
	The weighted-averages for key assumptions used in determining the fair value of options granted during the years ended December 31, 2014, 2013, and 2012 are as follows:
			Year Ended December 31,
			2014				2013				2012
	Average volatility			29.9	%			28.6	%			32.6	%
	Risk-free interest rate			1.7	%			1.3	%			0.7	%
	Weighted-average expected life in years			5				4.5				4.8
	Dividend yield rate			0	%			0	%			0	%
	Stock Options
	A summary of option activity under all plans for the year ended December 31, 2014 is presented below:
			Options				Weighted-				Weighted-			Aggregate
							Average				Average			Intrinsic
							Exercise				Remaining			Value(1)
							Price				Contractual
											Term (Years)
														(in thousands)
	Outstanding as of December 31, 2013			10,771,755			$	15.39
	Options granted			1,661,862				15.04
	Options exercised			(65,000	)			10.79
	Options cancelled			(135,398	)			15.74
	Options expired			(861,328	)			18.48
	Outstanding as of December 31, 2014			11,371,891			$	15.12				4.62		$	1,815
	Exercisable as of December 31, 2014			6,281,300			$	16.95				3.54		$	871
	-1	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s common stock for those awards that have an exercise price below the estimated fair value at December 31, 2014.
	A summary of option activity under all plans for the year ended December 31, 2013 is presented below:
			Options				Weighted-				Weighted-			Aggregate
							Average				Average			Intrinsic
							Exercise				Remaining			Value(1)
							Price				Contractual
											Term (Years)
														(in thousands)
	Outstanding as of December 31, 2012			8,278,766			$	18
	Options granted			3,598,725				12.09
	Options exercised			(4,200	)			13.07
	Options cancelled			(403,370	)			12.88
	Options expired			(698,166	)			30.84
Outstanding as December 31, 2013			10,771,755			$	15.39				4.88		$	20,343
Exercisable as of December 31, 2013			5,154,201			$	18.86				3.37		$	5,756
(1)  The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s common stock for those awards that have an exercise price below the estimated fair value at December 31, 2013.
For the years ended December 31, 2014, 2013, and 2012, the Company recorded stock option expense related to employees under all plans of $6.7 million, $5.9 million, and $6.5 million, respectively.
Information relating to option grants and exercises is as follows:
	Year Ended December 31,
	2014				2013				2012
	(in thousands, except per share data)
Weighted-average grant date fair value		$	4.02			$	2.79			$	3.01
Intrinsic value of options exercised			144				—				1,546
Cash received			571				55				333
Total fair value of the options vested during the year			6,407				6,067				6,809
A summary of the status of the Company’s nonvested options as of December 31, 2014, and changes during the year ended December 31, 2014, are presented below:
		Options				Weighted-Average
						Grant Date
						Fair Value
Nonvested as of December 31, 2013			5,617,554			$	3.12
Options granted			1,661,862				4.02
Options vested			(2,053,427	)			3.12
Options forfeited			(135,398	)			5.6
Nonvested as of December 31, 2014			5,090,591				3.34
A summary of the status of the Company’s nonvested options as of December 31, 2013, and changes during the year ended December 31, 2013, are presented below:
		Options				Weighted-Average
						Grant Date
						Fair Value
Nonvested as of December 31, 2012			3,849,866			$	4.01
Options granted			3,598,725				2.79
Options vested			(1,427,667	)			4.25
Options forfeited			(403,370	)			4.13
Nonvested as of December 31, 2013			5,617,554				3.12
As of December 31, 2014, there was $11.9 million of total unrecognized compensation cost, net of forfeitures, related to nonvested stock option based compensation arrangements granted under the Company’s 2005 Equity Incentive Award Plan, or the 2005 Plan. The cost is expected to be recognized over a weighted-average period of 2.3 years and will be adjusted for future changes in estimated forfeitures.
Deferred Stock Units
Beginning in 2007, the Company granted restricted stock awards in the form of deferred stock units, or DSUs, to certain employees and members of the Board of Directors with a vesting period of up to five years. The grantee receives one share of common stock at a specified future date for each DSU awarded. The DSUs may not be sold or otherwise transferred until certificates of common stock have been issued, recorded, and delivered to the participant. The DSUs do not have any voting or dividend rights prior to the issuance of certificates of the underlying common stock. The share-based expense associated with these grants was based on the Company’s common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period.  The Company recorded a total expense of $2.0 million, $0.6 million, and $0.5 million for the years ended December 31, 2014, 2013, and 2012, respectively, for these DSU awards.
As of December 31, 2014, there was $5.8 million of total unrecognized compensation cost, net of forfeitures, related to nonvested DSU-based compensation arrangements granted under the 2005 Plan. The cost is expected to be recognized over a weighted-average period of 2.4 years and will be adjusted for future changes in estimated forfeitures.
Additionally, prior to the Company’s IPO, the Company issued DSUs that were treated as an accounting exchange for expiring stock options, whereby the fair value of the expiring stock options equaled the fair value of the DSUs at the date of the exchange. As such, the Company did not record any expense related to these award modifications.
Information relating to DSU grants and deliveries is as follows:
		Total DSUs Issued				Total Fair Market
						Value of DSUs Issued
						as Compensation(1)
						(in thousands)
DSUs outstanding at December 31, 2012			111,731
DSUs granted(2)			100,675			$	1,000
DSUs forfeited			(20,048	)
DSUs surrendered for taxes			(13,783	)
Common stock delivered for DSUs			(80,080	)
DSUs outstanding at December 31, 2013			98,495
DSUs granted			456,406			$	6,474
DSUs forfeited			(994	)
DSUs surrendered for taxes			(10,670	)
Common stock delivered			(40,227	)
DSUs outstanding at December 31, 2014			503,010
(1)	The total FMV is derived from the number of DSUs granted times the current stock price on the date of grant.
(2)	76,000 total expiring options were exchanged for 20,374 DSUs, in aggregate in 2013.
Equity Awards to Consultants
The Company has entered into various consulting agreements with Company stockholders and outside consultants. Consulting expenses are accrued as services are rendered. Consulting services are paid in cash and/or in common stock or stock options. Share-based compensation expense is recorded over the service period based on the estimated fair market value of the equity award at the date services are performed or upon completion of all services under the agreement. During the year ended December 31, 2014, the Company recorded an immaterial amount of share-based compensation related to the issuance of stock and stock options for services rendered by consultants. For the years ended December 31, 2013 and 2012, the Company did not record any share-based compensation expense for services rendered by consultants.
The Company recorded share-based compensation expense under all plans and is included in the Company’s consolidated statement of operations as follows:
		Year Ended December 31,
		2014				2013				2012
		(in thousands)
Cost of revenues		$	1,678			$	1,503			$	1,794
Operating expenses:
Selling, distribution and marketing			137				132				143
General and administrative			6,800				4,701				4,593
Research and development			665				699				895
Total share-based compensation		$	9,280			$	7,035			$	7,425

Note_16_Employee_Benefits

Note 16 - Employee Benefits	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	16. Employee Benefits
	401(k) plan
	The Company has a defined contribution 401(k) plan, or the Plan, whereby eligible employees voluntarily contribute up to a defined percentage of their annual compensation. The Company matches contributions at a rate of 50% on the first 4% of employee contributions, or up to 2% of their annual compensation, and pays the administrative costs of the Plan. Employer contributions vest over four years. Total employer contributions for the years ended December 31, 2014, 2013, and 2012 were approximately $0.7 million, $0.6 million, and $0.5 million, respectively.
	Defined Benefit Pension Plan
	In connection with the Merck API Transaction, the Company assumed an obligation associated with a defined-benefit plan for eligible employees of AFP.  This plan provides benefits to the employees from the date of retirement and is based on the employee’s length of time with the Company.  The calculation is based on a statistical calculation combining a number of factors that include the employee’s age, length of service, and AFPs turnover rate.
	The liability under the plan is based on a discount rate of 1.75% as of December 31, 2014.  The liability is included in accrued liabilities in the accompanying consolidated balance sheets. The plan is currently unfunded, and the benefit obligation under the plan was $1.1 million at December 31, 2014.   Expense under the plan was $0.2 million for the year ended December 31, 2014.  The Company recorded an unrecognized gain of $0.2 million in its accumulated other comprehensive loss during the year ended December 31, 2014 related to the change in actuarial valuation of the Company’s defined benefit pension plan.

Note_17_Commitments_and_Contin

Note 17 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	17. Commitments and Contingencies
	Distribution Agreement with Actavis, Inc.
	In May 2005, the Company entered into an agreement to grant certain exclusive marketing rights for its enoxaparin product to Andrx Pharmaceuticals, Inc., or Andrx, which generally extends to the U.S. retail pharmacy market. To obtain such rights, Andrx made a non-refundable, upfront payment of $4.5 million to the Company upon execution of the agreement which was classified as deferred revenues. Under the agreement, the Company is paid a fixed cost per unit sold to Andrx and also shares in the gross profits (as defined) from Andrx’s sales of the product in the U.S. retail pharmacy market. In November 2006, Watson Pharmaceuticals, Inc., or Watson, acquired Andrx and all of the rights and obligations associated with the agreement. In January 2013, Watson adopted Actavis, Inc. as its new global name. The agreement has a term that expires in January 2019 and can be extended by Actavis for an additional three years. The agreement may only be terminated prior to the end of the term by either party in the case of a breach of contract or insolvency of the other party, by the Company if Actavis fails to purchase a minimum number of units and by Actavis if an infringement claim is made against Actavis.
	In January 2012, the Company launched enoxaparin, beginning the seven-year period in which Actavis has the exclusive marketing rights for the Company’s enoxaparin product in the U.S. retail pharmacy market and the start of the Company’s recognition of the $4.5 million deferred revenue over this period on a straight-line basis. Actavis has an option to renew the agreement for an additional three years.  As of December 31, 2014 and 2013, the balance of the deferred revenue was $2.6 million and $3.3 million, respectively.
	The Company manufactures its enoxaparin product for the retail market according to demand specifications of Actavis. Upon shipment of enoxaparin to Actavis, the Company recognizes product sales at an agreed transfer price and records the related cost of products sold. Based on the terms of the Company’s distribution agreement with Actavis, the Company is entitled to a share of the ultimate profits based on the eventual net revenue from enoxaparin sales by Actavis to the end user less the agreed transfer price originally paid by Actavis to the Company. Actavis provides the Company with a quarterly sales report that calculates the Company’s share of Actavis’ enoxaparin gross profit. The Company records its share of Actavis’ gross profit as a component of net revenue.
	Supply Agreement with MannKind Corporation
	On July 31, 2014, the Company entered in a supply agreement with MannKind Corporation, or MannKind, pursuant to which the Company will manufacture for and supply to MannKind certain quantities of recombinant human insulin, or RHI, for use in MannKind’s product Afrezza®. Under the terms of the supply agreement, the Company will be responsible for manufacturing the RHI in accordance with MannKind’s specifications and agreed-upon quality standards.  MannKind has agreed to purchase annual minimum quantities of RHI under the supply agreement of an aggregate amount of approximately €120.1 million, or approximately $146.0 million, in calendar years 2015 through 2019.
	MannKind paid a non-refundable reservation fee to the Company in the amount of €11.0 million, or approximately $14.0 million.  Under the agreement, the non-refundable reservation fee is considered as partial payment for the purchase commitment quantity for 2015. The Company classified the amount as deferred revenue.  As of December 31, 2014, the balance of the deferred revenue was €11.0 million, or $13.4 million.
	Unless earlier terminated, the term of the supply agreement expires on December 31, 2019 and can be renewed for additional, successive two-year terms upon 12 months’ written notice given prior to the end of the initial term or any additional two-year term.  MannKind and the Company each have customary termination rights, including termination for material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy, or insolvency of the other party. In addition, MannKind may terminate the supply agreement upon two years’ prior written notice to the Company without cause or upon 30 days prior written notice to the Company if a controlling regulatory authority withdraws approval for Afrezza®; provided, however, in the event of a termination pursuant to either of these scenarios, the provisions of the supply agreement require MannKind to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination.
	In January 2015, the Company entered into a supply option agreement with MannKind, pursuant to which MannKind will have the option to purchase RHI, for use in MannKind’s product Afrezza®, in addition to the amounts specified in the July 2014 supply agreement. Under the agreement, MannKind has the option to purchase additional RHI in calendar years 2016 through 2019.  In the event MannKind elects not to exercise its minimum annual purchase option for any year, MannKind shall pay the Company a capacity cancellation fee.
	Operating Lease Agreements
	The Company leases real and personal property, in the normal course of business, under various non-cancelable operating leases. The Company, at its option, can renew a substantial portion of its leases, at the market rate, for various renewal periods ranging from one to six years. Rental expense under these leases for the years ended December 31, 2014, 2013 and 2012 was approximately $3.1 million, $3.1 million, and $3.9 million, respectively.
	Future minimum rental payments under operating leases that have initial or remaining non-cancelable lease terms in excess of 12 months for fiscal years ending December 31 are as follows:
		Operating
		Leases
		(in thousands)
	2015	$	2,585
	2016		1,552
	2017		1,356
	2018		843
	2019		675
		$	7,011
	Purchase Commitments
	As of December 31, 2014, the Company has entered into commitments to purchase equipment and raw materials for an aggregate amount of approximately $6.8 million. The Company anticipates that most of these commitments will be fulfilled by 2016.
	The Company has entered into agreements with a Chinese governmental entity to acquire land-use rights to real property in Nanjing, China. Under the terms of these agreements, the Company has committed to invest capital in its wholly-owned subsidiary, ANP, and to develop these properties as an API manufacturing facility for the Company’s pipeline. In conjunction with these agreements, ANP modified its business license on July 3, 2012 to increase its authorized capital. As of December 31, 2014, the Company had invested approximately $45.0 million in ANP of its registered capital commitment of $61.0 million. The Company has committed to invest an additional $16.0 million in ANP, which is currently due by December 2017. This requirement to invest in ANP will result in cash being transferred from the U.S. parent company to ANP.
	Per these agreements, in January 2010, the Company acquired certain land-use rights with a carrying value of $1.2 million. In addition, the Company purchased additional land-use rights in November 2012 for $1.3 million. The Company is committed to spend approximately $15.0 million in land development. The agreements require the construction of fixed assets on the property and specified a timetable for the construction of these fixed assets. The current pace of development of the property is behind the schedules described in the purchase agreements and, per the purchase agreement, potential monetary penalties could result if the development is delayed or not completed in accordance with the guidelines stated in the purchase agreements. During the year ended December 31, 2014, the Company invested $7.2 million to fund the Company’s research and development pipeline for ANP.

Note_18_Litigation

Note 18 - Litigation	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Legal Matters and Contingencies [Text Block]	18. Litigation
	Enoxaparin Patent Litigation
	In September 2011, Momenta Pharmaceuticals, Inc., or Momenta, a Boston-based pharmaceutical company, and Sandoz Inc, or Sandoz, the generic division of Novartis, initiated litigation against the Company for alleged patent infringement of two patents related to testing methods for batch release of enoxaparin, which the Company refers to as the “‘886 patent” and the “‘466 patent.” The lawsuit was filed in the United States District Court for the District of Massachusetts, or the District Court. In October 2011, the District Court issued a preliminary injunction barring the Company from selling its generic enoxaparin product and also requiring Momenta and Sandoz to post a $100.1 million bond. The preliminary injunction was stayed by the United States Court of Appeals for the Federal Circuit, or Federal Circuit, in January 2012, and reversed by the Federal Circuit in August 2012.
	In January 2013, the Company moved for summary judgment of non-infringement of both patents. Momenta and Sandoz withdrew their allegations as to the ‘466 patent, and in July 2013, the District Court granted the Company’s motion for summary judgment of non-infringement of the ‘886 patent and denied Momenta and Sandoz’s motion for leave to amend infringement contentions. On January 24, 2014, the District Court judge entered final judgment in the Company’s favor on both patents. Momenta and Sandoz also filed a motion to collect attorney’s fees and costs relating to a discovery motion which the District Court granted. The parties have briefed the amount of attorney’s fees that should be imposed, which the Company believes should not exceed an amount of approximately $40 thousand. On January 30, 2014, Momenta and Sandoz filed a notice of appeal to the Federal Circuit appealing the court’s final judgment including summary judgment denying Momenta and Sandoz’s motion for leave to amend their infringement contentions. The Company intends to attempt to collect the $100.1 million bond posted by Momenta and Sandoz following the appeal. Momenta filed its opening appeal brief on June 27, 2014, the Company filed its responding brief on September 25, 2014, and Momenta filed its reply brief on November 13, 2014. The Federal Circuit has scheduled oral argument for May 4, 2015.
	False Claims Act Litigation
	In January 2009, the Company filed a qui tam complaint in the U.S. District Court for the Central District of California alleging that Aventis Pharma S.A., or Aventis, through its acquisition of a patent through false and misleading statements to the U.S. Patent and Trademark Office, as well as through false and misleading statements to the FDA, overcharged the federal and state governments for its Lovenox® product. If the Company is successful in this litigation, it could be entitled to a portion of any damage award that the government ultimately may recover from Aventis. In October 2011, the District Court unsealed the Company’s complaint. Since the complaint was unsealed, this case has steadily progressed and remains pending.
	On February 28, 2014, Aventis filed a motion for summary judgment on the issue of the adequacy of the Company’s notice letter to the government, and the District Court denied Aventis’ motion for summary judgment in a final order it issued on May 12, 2014. On June 9, 2014, at Aventis’ request, the District Court issued an order certifying for appeal its order denying Aventis’ motion for summary judgment. On June 9, 2014, Aventis filed with the United States Court of Appeals for the Ninth Circuit a petition for permission to appeal the District Court’s denial of Aventis’ motion for summary judgment, and the Company filed an opposition to Aventis’ petition on June 19, 2014. On August 22, 2014, the Court of Appeals granted Aventis’ petition. The parties have completed and filed their respective appeal briefs with the Ninth Circuit. A date for oral argument has not yet been set by the Ninth Circuit.
	The District Court set an evidentiary hearing for July 7, 2014 on the “original source” issue, a key element under the False Claims Act. The evidentiary hearing was conducted as scheduled, from July 7, 2014 through July 10, 2014. The Company filed its post-hearing brief on August 11, 2014, Aventis filed its post-hearing brief on September 10, 2014, and the Company filed its reply brief on September 24, 2014. The District Court conducted a hearing for closing argument on the original source issue on October 10, 2014. The original source issue currently is under submission with the District Court.
	California Employment Litigation
	On January 6, 2015, the Company received a formal demand from Plaintiff’s counsel in an employment related lawsuit captioned Eva Hernandez v. International Medication Systems Limited, in connection with a complaint originally filed on February 4, 2013 in the Superior Court of California County of Los Angeles, by plaintiff Eva Hernandez on behalf of herself and others similarly situated. Plaintiff’s counsel has indicated an intent to file a motion for class certification, which currently is set to be filed by April 16, 2015. Plaintiff’s current complaint includes alleged violations of the California Labor Code stemming from the Company’s alleged timekeeping practices, as well as other similar and related claims brought under California law. In her current complaint, Plaintiff seeks damages and related remedies under California law, as well as various penalty payments under the California Labor Code, on behalf of herself and others similarly situated. The Company intends to vigorously defend against these claims, to which the Company believes it has substantial factual and legal defenses.  In light of such factual and legal defenses, the Company believes the possibility of a material loss on the merits of the action is remote.
	Other Litigation
	The Company is also subject to various other claims and lawsuits arising in the ordinary course of business. In the opinion of management, the ultimate resolution of these matters is not expected to have a materially adverse effect on its financial position, results of operations, or cash flows; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.

Note_19_Subsequent_Event

Note 19 - Subsequent Event	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	19. Subsequent Event
	Equipment Loan — Due January 2019
	In January 2015, the Company drew down $6.2 million from its $8.0 million revolving credit facility with East West Bank which was entered into in July 2013.  Subsequently, the facility was then converted in an equipment loan with an outstanding principal balance of $6.2 million. Borrowings under the facility are secured by equipment purchased with the debt proceeds.  The Company entered into a fixed interest rate swap contract on this facility to exchange floating rate for a fixed interest payment over the life of the facility without the exchange of the underlying notional debt amount. The facility bears interest at a fixed rate of 4.48% and matures in January 2019.
	Supply Option Agreement with MannKind Corporation
	In January 2015, the Company entered into a supply option agreement with MannKind, pursuant to which MannKind will have the option to purchase RHI, for use in MannKind’s product Afrezza®, in addition to the amounts specified in the July 2014 supply agreement. Under the agreement, MannKind has the option to purchase additional RHI in calendar years 2016 through 2019.  In the event MannKind elects not to exercise its minimum annual purchase option for any year, MannKind shall pay the Company a capacity cancellation fee.

Note_20_Quarterly_Financial_Da

Note 20 - Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	20. Quarterly Financial Data (Unaudited)
		2014 Quarters
		First			Second			Third			Fourth
	Net revenues
	Finished pharmaceutical products	$	45,870		$	48,901			53,729			49,980
	API		—			102			5,982			5,897
	Total net revenues	$	45,870		$	49,003		$	59,711		$	55,877
	Gross profit
	Finished pharmaceutical products	$	12,509			14,961			12,122			13,132
	API		—			35			(331	)		(1,172	)
	Total gross profit	$	12,509		$	14,996		$	11,791		$	11,960
	Net loss	$	(1,619	)	$	(1,180	)	$	-5,379		$	(2,521	)
	Weighted-average shares used to compute net income per common share
	Basic		38,769			39,767			44,644			44,648
	Diluted		38,769			39,767			44,644			44,648
	Net loss per common share
	Basic	$	(0.04	)	$	(0.03	)	$	(0.12	)	$	(0.06	)
	Diluted	$	(0.04	)	$	(0.03	)	$	(0.12	)	$	(0.06	)
		2013 Quarters
		First			Second			Third			Fourth
	Net revenue
	Finished pharmaceutical products	$	52,963		$	62,524		$	59,318		$	54,876
	API		—			—			—			—
	Total net revenues	$	52,963		$	62,524		$	59,318		$	54,876
	Gross profit
	Finished pharmaceutical products	$	19,558		$	27,489		$	20,280		$	19,629
	API		—			—			—			—
	Total gross profit	$	19,558		$	27,489		$	20,280		$	19,629
	Net income (loss)	$	2,383		$	7,810		$	(160	)	$	1,829
	Weighted-average shares used to compute net loss per common share
	Basic		38,707			38,708			38,709			38,724
	Diluted		38,845			38,847			38,709			39,141
	Net income (loss) per common share
	Basic	$	0.06		$	0.2		$	0		$	0.05
	Diluted	$	0.06		$	0.2		$	0		$	0.05
	Net income (loss) per common share amounts for the fiscal quarters have been calculated independently and may not in the aggregate equal the amount for the full year.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
	All significant intercompany activity has been eliminated in the preparation of the consolidated financial statements. Some information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles, or GAAP, have been condensed or omitted pursuant to those rules and regulations.
	The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: International Medication Systems, Limited, or IMS; Amphastar Laboratories, Inc.; Armstrong Pharmaceuticals, Inc., or Armstrong; Amphastar Nanjing Pharmaceuticals Co., Ltd., or ANP; and Amphastar France Pharmaceuticals, S.A.S., or AFP.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for doubtful accounts and discounts, liabilities for product returns and chargebacks, reserves for excess or unsellable inventory, impairment of long-lived and intangible assets and goodwill, self-insured claims, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, fair market values of the Company’s common stock, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency
	The functional currency of the Company and its domestic and Chinese subsidiaries is the U.S. dollar, or USD.  The Company’s Chinese subsidiary, ANP, maintains its books of record in Chinese Yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign exchange gains and losses are reflected in the Company’s statement of operations.  The Company’s French subsidiary, AFP, maintains its books of record in Euros, which is the local currency in France and has been determined to be its functional currency. These books are translated to USD at the average exchange rates during the period.  Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date.  Equity is translated at the prevailing rate of exchange at the date of the equity transactions.  Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive income (loss).  Additionally, the Company does not undertake hedging transactions to cover its foreign currency exposure.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss)
	For the Company’s recently acquired subsidiary in France, the Euro, which is the local currency, has been determined to be the functional currency. The results of the Company’s French subsidiary’s operations are translated to U.S. dollars at the average exchange rates during the period.
	For the year ended December 31, 2014, the Company includes its foreign currency translation adjustment as well as the change to its actuarial valuation on the Company’s defined benefit pension plan (see Note 16) as part of its comprehensive loss. For the years ended December 31, 2013 and 2012, net income (loss) equaled total comprehensive income (loss).
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Costs
	For the years ended December 31, 2014, 2013, and 2012, the Company included shipping and handling costs of approximately $2.5 million, $2.4 million, and $2.1 million, respectively, in selling, distribution and marketing expenses in the accompanying consolidated statements of operations.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs
	Research and development costs are charged to expense as incurred and consist of costs incurred to further the Company’s research and development activities including salaries and related employee benefits, costs associated with clinical trials, nonclinical research and development activities, regulatory activities, research-related overhead expenses and fees paid to external service providers.
	The Company may produce inventories prior to or with the expectation of receiving marketing authorization in the near term, based on operational decisions about the most effective use of existing resources. This inventory is referred to as pre-launch inventory. The Company’s policy is to expense pre-launch inventory as research and development costs, as incurred, until the drug candidate receives marketing authorization. As a result of the policy, while marketing authorization may have been received by the end of a reporting period, any inventories produced prior to such authorization are expensed. If marketing authorization is received and previously expensed pre-launch inventory is sold, such sales may contribute up to a 100% margin to the Company’s operating results. Pre-launch inventory costs include cost of work in process materials and finished drug products.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments
	The carrying amounts of cash and cash equivalents, short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. A majority of the Company’s long-term obligations consist of variable rate debt and their carrying value approximates fair value. Their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. However, the Company has one fixed-rate, long-term mortgage for which the carrying value differs from the fair value and is not remeasured on a recurring basis (see Note 13).
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash, money market funds, certificates of deposit and highly liquid investments purchased with original maturities of three months or less.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash and Restricted Short-Term Investments
	Restricted cash and restricted short-term investments as of December 31, 2014 and 2013 included $1.5 million and $1.3 million, respectively, in certificates of deposit, which is the collateral required for the Company to qualify for workers’ compensation self-insurance and is available to meet the Company’s workers’ compensation obligations on a current basis, as needed. These funds are classified as current assets. The Company’s short-term investments are classified as held- to-maturity and consist of certificates of deposit purchased with maturities greater than three months but mature within one year of the date of purchase. The estimated fair value of each investment approximates its amortized cost.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts Receivable
	The Company evaluates the collectability of accounts receivable based on a combination of factors. When the Company is aware of circumstances that may impair a customer’s ability to pay subsequent to the original sale, the Company will record a specific allowance to reduce the amounts due to the amount the Company reasonably believes will be collected. For all other customers, the Company recognizes an allowance for doubtful accounts based on factors that include the length of time the receivables are past due, industry and geographic concentrations, the current business environment and historical collection experience.
Inventory, Policy [Policy Text Block]	Inventories
	Inventories are stated at the lower of cost or market, using the first-in, first-out method. Provisions are made for slow-moving, unsellable, or obsolete items. Inventories consist of currently marketed products and products manufactured under contract.
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment
	Property, plant and equipment are stated at cost or, in the case of assets acquired in a business combination, at fair value on the purchase date. Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the related assets as follows:
	Buildings (years)	20	-	31
	Machinery and equipment (years)	2	-	12
	Furniture and fixtures (years)	3	-	7
	Automobiles (years)	4	-	5
	Leasehold improvements	Lesser of remaining lease term or useful life
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and Intangible Assets
	Intangible assets with finite lives are amortized over the period the asset is expected to contribute directly or indirectly to the future cash flows of the Company. Product rights are amortized over their estimated useful lives ranging from five to 15 years on a straight-line basis since their projected revenues are expected to be consistent each year. Patents and trademarks are amortized on a straight-line basis over their estimated useful lives, generally ranging from 10 to 20 years. Land-use rights are amortized on a straight-line basis over their useful lives, generally ranging from 37 to 50 years. In accordance with the Company’s accounting policy, the Company tests all intangible assets on an annual basis and between annual tests whenever there is an indication of impairment.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets
	The Company reviews long-lived assets and definite-lived intangibles for impairment in the fourth quarter of each year or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets (assets to be held and used) or fair value less cost to sell (assets to be disposed of). The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized.
Income Tax, Policy [Policy Text Block]	Deferred Income Taxes
	The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. The Company has adopted the with-and-without methodology for determining when excess tax benefits from the exercise of share-based awards are realized. Under the with-and-without methodology, current year operating loss deductions and prior-year operating loss carryforwards are deemed to be utilized prior to the utilization of current-year excess tax benefits from share-based awards.
Self Insurance Reserve [Policy Text Block]	Self-Insured Claims
	The Company is primarily self-insured, up to certain limits, for workers’ compensation claims. The Company has purchased stop-loss insurance, which will reimburse the Company for individual claims in excess of $350,000 annually or aggregate claims exceeding $1.9 million annually. Operations are charged with the cost of claims reported and an estimate of claims incurred but not reported. A liability for unpaid claims and the associated claim expenses, including incurred but not reported losses, is actuarially determined and reflected in accrued liabilities in the accompanying consolidated balance sheets. Total expense under the program was approximately $1.0 million, $0.8 million, and $1.2 million, for the years ended December 31, 2014, 2013 and 2012, respectively. The self-insured claims liability was $2.2 million and $2.0 million at December 31, 2014 and 2013, respectively. The determination of such claims and expenses and the appropriateness of the related liability is reviewed periodically and updated, as necessary. Changes in estimates are recorded in the period identified.
Correction of an Immaterial Error [Policy Text Block]	Correction of an Immaterial Error
	During the fourth quarter of 2014, the Company identified an immaterial error in the Company’s previously reported consolidated financial statements primarily pertaining to the year ended December 31, 2013 as the result of not capitalizing interest expense on certain foreign construction projects during the year. The Company corrected the immaterial error in the fourth quarter of 2014, resulting in a decrease to net loss by $0.3 million, which has no impact to the Company’s basic and diluted loss per share for the year ended December 31, 2014. Based on management's evaluation of the materiality of the error from a qualitative and quantitative perspective as required by authoritative guidance, the Company concluded that correcting the error had no material impact on any of the Company's previously issued interim financial statements and had no effect on the trend of financial results.
Business Combinations Policy [Policy Text Block]	Business Combinations
	Business combinations are accounted for in accordance with Accounting Standards Codification, or ASC 805, Business Combinations, using the acquisition method of accounting. The acquisition method of accounting requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received.
	Acquisition-related costs are costs the Company incurs to effect a business combination. The Company accounts for acquisition-related costs as expenses in the periods in which the costs are incurred.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board, or FASB, issued an Accounting Standard Update to the accounting guidance to address the diversity in practice related to the financial statement presentation of unrecognized tax benefits as either a reduction of a deferred tax asset or a liability when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.
	In April 2014, the FASB issued an accounting standards update that raises the threshold for disposals to qualify as discontinued operations and allows companies to have significant continuing involvement with and continuing cash flows from or to the discontinued operation. It also requires additional disclosures for discontinued operations and new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation. This guidance will be effective for fiscal years beginning after December 15, 2014, which will be the Company's fiscal year 2015, with early adoption permitted. The Company does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.
	In May 2014, the FASB issued an accounting standards update that creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and will be effective for fiscal years beginning after December 15, 2016, which will be the Company's fiscal year 2017. The Company has not yet evaluated the potential impact of adopting the guidance on the Company's consolidated financial statements.
	In June 2014, the FASB issued an accounting standards update that requires a performance target that affects vesting of a share-based payment award and that could be achieved after the requisite service period to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized over the required service period, if it is probable that the performance target will be achieved. This guidance will be effective for fiscal years beginning after December 15, 2015, which will be the Company's fiscal year 2016, with early adoption permitted. The Company does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.
	In August 2014, the FASB issued an accounting standards update that will require management to evaluate if there is substantial doubt about the Company’s ability to continue as a going concern and, if so, to disclose this in both interim and annual reporting periods.  This guidance will become effective for the Company’s annual filing for the period ending December 31, 2016 and interim periods thereafter, and allows for early adoption.  The Company does not expect the adoption of the guidance will have a material impact on the Company’s consolidated financial statements.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Property Plant and Equipment Useful Life [Table Text Block}	Buildings (years)	20	-	31
	Machinery and equipment (years)	2	-	12
	Furniture and fixtures (years)	3	-	7
	Automobiles (years)	4	-	5
	Leasehold improvements	Lesser of remaining lease term or useful life

Note_3_Business_Acquisition_Ta

Note 3 - Business Acquisition (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]		Euros			U.S.
					Dollars
		(in thousands)
	At Closing, April 2014	€	13,252		$	18,352
	Dec-14		4,899			5,989
	Dec-15		3,186			3,873
	Dec-16		3,186			3,873
	Dec-17		500			607
		€	25,023		$	32,694
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]		Fair Value
		Euros			U.S.
					Dollars
		(in thousands)
	Inventory	€	15,565		$	21,554
	Real property		4,800			6,647
	Machinery & equipment		6,800			9,417
	Intangibles		80			111
	Goodwill		3,155			4,369
	Total assets acquired	€	30,400		$	42,098
	Accrued liabilities	€	2,425		$	3,358
	Deferred tax liabilities		3,155			4,369
	Total liabilities assumed		5,580			7,727
	Total fair value of consideration transferred	€	24,820		$	34,371
Business Acquisition, Pro Forma Information [Table Text Block]		Year Ended
		December 31,
		2014			2013
		(in thousands,
		except per share data)
	Net revenues	$	212,745		$	243,786
	Net income (loss)		(11,928	)		12,969
	Diluted net income (loss) per share	$	(0.28	)	$	0.33

Note_4_Revenue_Recognition_Tab

Note 4 - Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2014
Revenue Recognition Disclosure [Abstract]
Schedule of Chargeback Liability [Table Text Block]		Year Ended December 31,
		2014			2013
		(in thousands)
	Beginning balance	$	18,104			$	11,898
	Provision related to sales made in the current period		156,235				213,075
	Credits issued to third parties		(162,467	)			(206,869	)
	Ending balance	$	11,872			$	18,104
Schedule of Product Returns Liability [Table Text Block]		Year Ended December 31,
		2014			2013
		(in thousands)
	Beginning balance	$	4,592			$	2,673
	Provision for product returns		(714	)			2,711
	Credits issued to third parties		(1,470	)			(792	)
	Ending balance	$	2,408			$	4,592

Note_5_Income_Loss_Per_Share_T

Note 5 - Income (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]		Year Ended December 31,
		2014			2013		2012
		(in thousands, except per share data)
	Basic and dilutive numerator:
	Net income (loss)	$	(10,699	)	$	11,862	$	18,094
	Denominator:
	Common shares outstanding		41,957			38,705		38,578
	Contingently issuable shares - vested DSUs		—			7		2
	Weighted-average common shares outstanding—basic		41,957			38,712		38,580
	Net effect of dilutive securities:
	Stock options		—			104		241
	Contingently issuable shares – nonvested DSUs		—			67		119
	Weighted-average common shares outstanding—diluted		41,957			38,883		38,940
	Net income (loss) per common share—basic	$	(0.25	)	$	0.31	$	0.47
	Net income (loss) per common share—diluted	$	(0.25	)	$	0.31	$	0.46

Note_6_Segment_Reporting_Table

Note 6 - Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]		Year Ended December 31,
		2014				2013				2012
		(in thousands)
	Net revenues:
	Finished pharmaceutical products	$	198,480			$	229,681			$	204,323
	API		11,981				—				—
	Total net revenues		210,461				229,681				204,323
	Gross profit (loss):
	Finished pharmaceutical products		52,724				86,956				90,303
	API		(1,468	)			—				—
	Total gross profit		51,256				86,956				90,303
	Operating expenses		69,239				69,466				64,906
	Income (loss) from operations		(17,983	)			17,490				25,397
	Non-operating income (expenses)		(165	)			(263	)			481
	Income (loss) before income taxes	$	(18,148	)		$	17,227			$	25,878
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]		Net Revenue										Long-Lived Assets
		Year Ended December 31,										December 31,
		2014			2013				2012			2014			2013
		(in thousands)
	U.S.	$	198,480			$	229,681			$	204,323		$	102,313		$	99,398
	China		—				—				—			22,170			17,221
	France		11,981				—				—			13,806			—
	Total	$	210,461			$	229,681			$	204,323		$	138,289		$	116,619

Note_7_Customer_and_Supplier_C1

Note 7 - Customer and Supplier Concentration (Tables)	12 Months Ended
	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]		% of Total Accounts						% of Net
		Receivable						Revenue
		December 31,						Year Ended December 31,
		2014			2013			2014			2013			2012
	Actavis, Inc.		18	%		44	%		30	%		35	%		35	%
	AmerisourceBergen		5	%		11	%		15	%		15	%		14	%
	Cardinal Health		15	%		7	%		14	%		13	%		13	%
	MannKind Corporation		21	%		—			2	%		—			—
	McKesson		13	%		13	%		22	%		26	%		27	%

Note_8_Fair_Value_Measurements1

Note 8 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis [Table Text Block]		Total		Quoted Prices in		Significant Other		Significant
				Active Markets		Observable Inputs		Unobservable Inputs
				for Identical		(Level 2)		(Level 3)
				Assets
				(Level 1)
		(in thousands)
	Cash equivalents:
	Money market accounts	$	42,994	$	42,994	$	—	$	—
	Restricted short-term investments:
	Certificates of deposit		1,495		1,495		—		—
	Fair value measurement as of December 31, 2014	$	44,489	$	44,489	$	—	$	—
	Cash equivalents:
	Money market accounts	$	41,183	$	41,183	$	—	$	—
	Restricted short-term investments:
	Certificates of deposit		1,325		1,325		—		—
	Fair value measurement as of December 31, 2013	$	42,508	$	42,508	$	—	$	—

Note_9_Goodwill_and_Intangible1

Note 9 - Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill [Table Text Block]		Weighted-Average Life (Years)				Original Cost		Accumulated Amortization		Net Book Value
						(in thousands)
	Definite-lived intangible assets
	Product rights		12			$	27,134	$	20,896	$	6,238
	Patents		10				293		78		215
	Trademarks		11				19		15		4
	Land-use rights		39				2,540		221		2,319
	Other intangible assets		1				505		505		—
	Subtotal		12				30,491		21,715		8,776
	Indefinite-lived intangible assets
	Trademark		*				29,225		—		29,225
	Goodwill
	Finished pharmaceutical products		*				280		—		280
	API		*				4,187		—		4,187
	AFP customers		*				97		—		97
	Subtotal		*				33,789		—		33,789
	As of December 31, 2014		*			$	64,280	$	21,715	$	42,565
		Weighted-Average Life (Years)				Original Cost		Accumulated Amortization		Net Book Value
						(in thousands)
	Definite-lived intangible assets
	Product rights		12			$	27,134	$	19,114	$	8,020
	Patents		10				298		50		248
	Trademarks		11				19		13		6
	Land-use rights		39				2,540		156		2,384
	Other intangible assets		1				505		505		—
	Subtotal		11				30,496		19,838		10,658
	Indefinite-lived intangible assets
	Trademark		*				29,225		—		29,225
	Goodwill
	Finished pharmaceutical products		*				280		—		280
	API		*				—		—		—
	Subtotal		*				29,505		—		29,505
	As of December 31, 2013		*			$	60,001	$	19,838	$	40,163
Schedule of Goodwill [Table Text Block]		December 31,
		2014			2013
		(in thousands)
	Beginning balance	$	280			$	280
	Goodwill related to acquisition of business		4,369				—
	Currency translation and other adjustments		(182	)			—
	Ending Balance	$	4,467			$	280
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]		(in thousands)
	2015	$	1,878
	2016		1,878
	2017		1,877
	2018		986
	2019		95
	Thereafter		2,062
	Total amortizable intangible assets		8,776
	Indefinite-lived intangibles		33,789
	Total intangibles (net of accumulated amortization)	$	42,565

Note_10_Inventories_Tables

Note 10 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]		December 31,
		2014			2013
		(in thousands)
	Raw materials and supplies	$	41,996		$	34,470
	Work in process		16,221			14,698
	Finished goods		24,755			26,501
	Total inventory		82,972			75,669
	Less reserve for excess and obsolete inventories		(640	)		(5,753	)
	Total inventory, net	$	82,332		$	69,916

Note_11_Property_Plant_and_Equ1

Note 11 - Property, Plant, and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]		December 31,
		2014			2013
		(in thousands)
	Building	$	67,760		$	58,898
	Leasehold improvements		23,960			23,834
	Land		7,020			5,805
	Machinery and equipment		104,819			93,617
	Furniture, fixtures, and automobiles		12,213			9,355
	Construction in progress		25,068			15,685
	Total property, plant, and equipment		240,840			207,194
	Less accumulated depreciation and amortization		(102,551	)		(90,575	)
	Total property, plant, and equipment, net	$	138,289		$	116,619

Note_13_Debt_Tables

Note 13 - Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]		December 31,
		2014		2013
		(in thousands)
	Loans with East West Bank
	Mortgage payable due January 2016	$	3,887	$	4,041
	Mortgage payable due September 2016		2,289		2,364
	Equipment loan paid off November 2014		—		783
	Line of credit facility due March 2016		—		—
	Equipment loan due April 2017		2,923		4,103
	Line of credit facility due January 2019		—		—
	Loans with Cathay Bank
	Mortgage payable due April 2021		4,549		4,624
	Revolving line of credit due May 2016		—		15,000
	Acquisition loan due April 2019		20,870		—
	Payment obligation to Merck		8,160		—
	Equipment under Capital Leases		1,022		1,258
	Total debt and capital leases		43,700		32,173
	Less current portion of long-term debt and capital leases		7,594		22,104
	Long-term debt, net of current portion and capital leases	$	36,106	$	10,069
Schedule of Maturities of Long-term Debt [Table Text Block]		Debt		Capital Leases		Total
		(in thousands)
	2015	$	7,243	$	403
	2016		12,973		301
	2017		3,131		298
	2018		2,203		126
	2019		13,076		—
	Thereafter		4,052		—
			42,678		1,128
	Less amount representing interest		—		106
		$	42,678	$	1,022	$	43,700

Note_14_Income_Taxes_Tables

Note 14 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]		Year Ended December 31,
		2014			2013			2012
		(in thousands)
	Income (loss) before income taxes:
	United States	$	(12,946	)	$	20,116		$	27,715
	Foreign		(5,202	)		(2,889	)		(1,837	)
	Total income (loss) before taxes	$	(18,148	)	$	17,227		$	25,878
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]		Year Ended December 31,
		2014			2013			2012
		(in thousands)
	Current provision (benefit):
	Federal	$	(131	)	$	3,306		$	(1,304	)
	State		193			541			(2,337	)
	Foreign		1,388			104			94
	Total current provision (benefit)		1,450			3,951			(3,547	)
	Deferred provision (benefit):
	Federal		(4,309	)		2,254			11,817
	State		(1,699	)		227			170
	Foreign		(2,891	)		(1,067	)		(656	)
	Total deferred provision (benefit)		(8,899	)		1,414			11,331
	Total provision (benefit) for income taxes	$	(7,449	)	$	5,365		$	7,784
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		Year Ended December 31,
		2014			2013			2012
	Statutory federal income tax (benefit)		(35.0	%)		35	%		35	%
	State tax expense, net of federal tax benefit		(5.4	)		2.9			(4.7	)
	Foreign income tax		1.8			0.3			0.1
	Qualified production activities deduction		—			(3.3	)		—
	Research and development credits		(6.4	)		(9.9	)		—
	Benefit for uncertain tax position		—			—			(3.0	)
	ISO portion of stock options deductions		4			6.3			4
	Other		—			(0.2	)		(1.3	)
	Effective tax rate (benefit)		(41.0	%)		31.1	%		30.1	%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]		December 31,
		2014			2013
		(in thousands)
	Deferred tax assets:
	Net operating loss carryforward	$	7,877		$	933
	State income taxes		270			290
	Inventory capitalization and reserve		6,843			5,800
	Deferred revenue		864			1,151
	Accrued payroll and benefits		1,571			1,465
	Share-based compensation		8,437			6,987
	Research and development credits		9,863			7,751
	Alternative minimum tax		447			406
	Accrued professional fees		568			885
	Product return allowance		1,221			2,092
	Accrued chargebacks		4,792			7,187
	Bad debt reserve		67			57
	Intangibles		3,861			—
	Accrued for workers’ compensation insurance		864			776
	Total deferred tax assets		47,545			35,780
	Deferred tax liabilities:
	Depreciation/amortization		15,649			13,920
	Intangibles		4,753			3,828
	Federal impact of state deferred taxes		2,910			2,397
	Other		937			575
	Total deferred tax liabilities		24,249			20,720
	Valuation Allowance		3,862			—
	Net deferred tax assets	$	19,434		$	15,060
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]		December 31,
		2014			2013
		(in thousands)
	Balance at the beginning of the year	$	4,186		$	3,532
	Additions based on tax positions related to the current year		655			766
	Deductions based on tax audit settlement		—			(93	)
	Deductions based on statute of limitations		(58	)		(19	)
	Balance at the end of the year	$	4,783		$	4,186

Note_15_Stockholders_Equity_Ta

Note 15 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]			Year Ended December 31,
			2014				2013				2012
	Average volatility			29.9	%			28.6	%			32.6	%
	Risk-free interest rate			1.7	%			1.3	%			0.7	%
	Weighted-average expected life in years			5				4.5				4.8
	Dividend yield rate			0	%			0	%			0	%
Schedule of Stock Options Roll Forward [Table Text Block]			Options				Weighted-				Weighted-			Aggregate
							Average				Average			Intrinsic
							Exercise				Remaining			Value(1)
							Price				Contractual
											Term (Years)
														(in thousands)
	Outstanding as of December 31, 2013			10,771,755			$	15.39
	Options granted			1,661,862				15.04
	Options exercised			(65,000	)			10.79
	Options cancelled			(135,398	)			15.74
	Options expired			(861,328	)			18.48
	Outstanding as of December 31, 2014			11,371,891			$	15.12				4.62		$	1,815
	Exercisable as of December 31, 2014			6,281,300			$	16.95				3.54		$	871
			Options				Weighted-				Weighted-			Aggregate
							Average				Average			Intrinsic
							Exercise				Remaining			Value(1)
							Price				Contractual
											Term (Years)
														(in thousands)
	Outstanding as of December 31, 2012			8,278,766			$	18
	Options granted			3,598,725				12.09
	Options exercised			(4,200	)			13.07
	Options cancelled			(403,370	)			12.88
	Options expired			(698,166	)			30.84
	Outstanding as December 31, 2013			10,771,755			$	15.39				4.88		$	20,343
	Exercisable as of December 31, 2013			5,154,201			$	18.86				3.37		$	5,756
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]		Year Ended December 31,
		2014				2013				2012
		(in thousands, except per share data)
	Weighted-average grant date fair value		$	4.02			$	2.79			$	3.01
	Intrinsic value of options exercised			144				—				1,546
	Cash received			571				55				333
	Total fair value of the options vested during the year			6,407				6,067				6,809
Schedule of Nonvested Share Activity [Table Text Block]			Options				Weighted-Average
							Grant Date
							Fair Value
	Nonvested as of December 31, 2013			5,617,554			$	3.12
	Options granted			1,661,862				4.02
	Options vested			(2,053,427	)			3.12
	Options forfeited			(135,398	)			5.6
	Nonvested as of December 31, 2014			5,090,591				3.34
			Options				Weighted-Average
							Grant Date
							Fair Value
	Nonvested as of December 31, 2012			3,849,866			$	4.01
	Options granted			3,598,725				2.79
	Options vested			(1,427,667	)			4.25
	Options forfeited			(403,370	)			4.13
	Nonvested as of December 31, 2013			5,617,554				3.12
Schedule of Share-based Compensation, Activity [Table Text Block]			Total DSUs Issued				Total Fair Market
							Value of DSUs Issued
							as Compensation(1)
							(in thousands)
	DSUs outstanding at December 31, 2012			111,731
	DSUs granted(2)			100,675			$	1,000
	DSUs forfeited			(20,048	)
	DSUs surrendered for taxes			(13,783	)
	Common stock delivered for DSUs			(80,080	)
	DSUs outstanding at December 31, 2013			98,495
	DSUs granted			456,406			$	6,474
	DSUs forfeited			(994	)
	DSUs surrendered for taxes			(10,670	)
	Common stock delivered			(40,227	)
	DSUs outstanding at December 31, 2014			503,010
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]			Year Ended December 31,
			2014				2013				2012
			(in thousands)
	Cost of revenues		$	1,678			$	1,503			$	1,794
	Operating expenses:
	Selling, distribution and marketing			137				132				143
	General and administrative			6,800				4,701				4,593
	Research and development			665				699				895
	Total share-based compensation		$	9,280			$	7,035			$	7,425

Note_17_Commitments_and_Contin1

Note 17 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]		Operating
		Leases
		(in thousands)
	2015	$	2,585
	2016		1,552
	2017		1,356
	2018		843
	2019		675
		$	7,011

Note_20_Quarterly_Financial_Da1

Note 20 - Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]		2014 Quarters
		First			Second			Third			Fourth
	Net revenues
	Finished pharmaceutical products	$	45,870		$	48,901			53,729			49,980
	API		—			102			5,982			5,897
	Total net revenues	$	45,870		$	49,003		$	59,711		$	55,877
	Gross profit
	Finished pharmaceutical products	$	12,509			14,961			12,122			13,132
	API		—			35			(331	)		(1,172	)
	Total gross profit	$	12,509		$	14,996		$	11,791		$	11,960
	Net loss	$	(1,619	)	$	(1,180	)	$	-5,379		$	(2,521	)
	Weighted-average shares used to compute net income per common share
	Basic		38,769			39,767			44,644			44,648
	Diluted		38,769			39,767			44,644			44,648
	Net loss per common share
	Basic	$	(0.04	)	$	(0.03	)	$	(0.12	)	$	(0.06	)
	Diluted	$	(0.04	)	$	(0.03	)	$	(0.12	)	$	(0.06	)
		2013 Quarters
		First			Second			Third			Fourth
	Net revenue
	Finished pharmaceutical products	$	52,963		$	62,524		$	59,318		$	54,876
	API		—			—			—			—
	Total net revenues	$	52,963		$	62,524		$	59,318		$	54,876
	Gross profit
	Finished pharmaceutical products	$	19,558		$	27,489		$	20,280		$	19,629
	API		—			—			—			—
	Total gross profit	$	19,558		$	27,489		$	20,280		$	19,629
	Net income (loss)	$	2,383		$	7,810		$	(160	)	$	1,829
	Weighted-average shares used to compute net loss per common share
	Basic		38,707			38,708			38,709			38,724
	Diluted		38,845			38,847			38,709			39,141
	Net income (loss) per common share
	Basic	$	0.06		$	0.2		$	0		$	0.05
	Diluted	$	0.06		$	0.2		$	0		$	0.05

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

Shipping, Handling and Transportation Costs

$2,500,000

$2,400,000

$2,100,000

Restricted Cash and Investments, Current

1,325,000

1,495,000

1,325,000

1,495,000

1,325,000

Finite-Lived Intangible Asset, Useful Life

11 years

12 years

Actuarially Determined Self-insurance Expense

1,000,000

800,000

1,200,000

Self-insurance Claims Liability

2,200,000

2,000,000

Net income (loss)

-2,521,000

-5,379,000

-1,180,000

-1,619,000

1,829,000

-160,000

7,810,000

2,383,000

-10,699,000

11,862,000

18,094,000

Annual Individual Reimbursement Coverage [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

Reinsurance Retention Policy, Excess Retention, Amount Reinsured

350,000

Aggregate Claims Coverage [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

Reinsurance Retention Policy, Excess Retention, Amount Reinsured

1,900,000

Restatement Adjustment [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

Net income (loss)

$300,000

Product Rights [Member] | Minimum [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life

5 years

Product Rights [Member] | Maximum [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life

15 years

Product Rights [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life

12 years

12 years

Patents and Trademarks [Member] | Minimum [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life

10 years

Patents and Trademarks [Member] | Maximum [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life

20 years

Land-Use Rights [Member] | Minimum [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life

37 years

Land-Use Rights [Member] | Maximum [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life

50 years

Land-Use Rights [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life

39 years

39 years

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment Estimated Useful Life	12 Months Ended
	Dec. 31, 2014
Building [Member] | Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment Useful Life	20 years
Building [Member] | Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment Useful Life	31 years
Machinery and Equipment [Member] | Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment Useful Life	2 years
Machinery and Equipment [Member] | Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment Useful Life	12 years
Furniture and Fixtures [Member] | Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment Useful Life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment Useful Life	7 years
Automobiles [Member] | Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment Useful Life	4 years
Automobiles [Member] | Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment Useful Life	5 years
Leasehold Improvements [Member] | Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment Estimated Useful Life [Line Items]
Leasehold improvements	Lesser of remaining lease term or useful life

Note_3_Business_Acquisition_De

Note 3 - Business Acquisition (Details)	0 Months Ended		0 Months Ended		12 Months Ended			0 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Jun. 01, 2014	Apr. 22, 2014	Jun. 01, 2014	Apr. 22, 2014	Dec. 31, 2014	Apr. 22, 2014	Dec. 31, 2014	Apr. 30, 2014	Apr. 30, 2014	Dec. 31, 2014	Dec. 31, 2014
		Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]
		Secured Term Loan With Cathay Bank [Member]	Secured Term Loan With Cathay Bank [Member]	Secured Term Loan With Cathay Bank [Member]	Secured Term Loan With Cathay Bank [Member]	Secured Term Loan With Cathay Bank [Member]	Minimum [Member]	USD ($)	EUR (€)	USD ($)	EUR (€)
		Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]
		Minimum [Member]				USD ($)
Note 3 - Business Acquisition (Details) [Line Items]
Business Combination, Consideration Transferred								$34.40	€ 24.80
Goodwill, Purchase Accounting Adjustments										4.4	3.2
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities										4.4	3.2
Debt Instrument, Face Amount						21.9
Debt Instrument, Interest Rate, Stated Percentage		4.00%					4.00%
Debt Instrument, Term	120 months		120 months
Debt Instrument, Maturity Date					22-Apr-19
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid						$12
Debt Instrument Loan Collateral Percentage				65.00%

Note_3_Business_Acquisition_De1

Note 3 - Business Acquisition (Details) - Acquisition of Merck Sharpe & Dohme’s Payment Terms

12 Months Ended

0 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

USD ($)

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Payment at Closing, April 2014 [Member]

Payment at Closing, April 2014 [Member]

Payment Due in December 2014 [Member]

Payment Due in December 2014 [Member]

Payment Due in December 2015 [Member]

Payment Due in December 2015 [Member]

Payment Due in December 2016 [Member]

Payment Due in December 2016 [Member]

Payment Due in December 2017 [Member]

Payment Due in December 2017 [Member]

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

Business Acquisition [Line Items]

Payment to Acquire Business, Gross

$18,352

$18,352

€ 13,252

$5,989

€ 4,899

$3,873

€ 3,186

$3,873

€ 3,186

$607

€ 500

$32,694

€ 25,023

Note_3_Business_Acquisition_De2

Note 3 - Business Acquisition (Details) - Acquired Assets and Liabilities Assumed	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 30, 2014	Apr. 30, 2014
In Thousands, unless otherwise specified	USD ($)	USD ($)	USD ($)	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]
				USD ($)	EUR (€)
Note 3 - Business Acquisition (Details) - Acquired Assets and Liabilities Assumed [Line Items]
Inventory				$21,554	€ 15,565
Real property				6,647	4,800
Machinery & equipment				9,417	6,800
Intangibles				111	80
Goodwill	4,467	280	280	4,369	3,155
Total assets acquired				42,098	30,400
Accrued liabilities				3,358	2,425
Deferred tax liabilities				4,369	3,155
Total liabilities assumed				7,727	5,580
Total fair value of consideration transferred				$34,371	€ 24,820

Note_3_Business_Acquisition_De3

Note 3 - Business Acquisition (Details) - Acquisition Pro Forma Information (Merck Sharpe & Dohme's API [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Merck Sharpe & Dohme's API [Member]
Note 3 - Business Acquisition (Details) - Acquisition Pro Forma Information [Line Items]
Net revenues	$212,745	$243,786
Net income (loss)	($11,928)	$12,969
Diluted net income (loss) per share (in Dollars per share)	($0.28)	$0.33

Note_4_Revenue_Recognition_Det

Note 4 - Revenue Recognition (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenue Recognition Disclosure [Abstract]
Product Return Rate, Percentage	1.10%	1.40%

Note_4_Revenue_Recognition_Det1

Note 4 - Revenue Recognition (Details) - Analysis of the Chargeback Liability (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Analysis of the Chargeback Liability [Abstract]
Beginning balance	$18,104	$11,898
Ending balance	11,872	18,104
Provision related to sales made in the current period	156,235	213,075
Credits issued to third parties	($162,467)	($206,869)

Note_4_Revenue_Recognition_Det2

Note 4 - Revenue Recognition (Details) - Analysis of the Product Return Liability (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Analysis of the Product Return Liability [Abstract]
Beginning balance	$4,592	$2,673
Ending balance	2,408	4,592
Provision for product returns	-714	2,711
Credits issued to third parties	($1,470)	($792)

Note_5_Income_Loss_Per_Share_D

Note 5 - Income (Loss) Per Share (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 5 - Income (Loss) Per Share (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)	$15.12	$15.39	$18
Equity Option [Member]
Note 5 - Income (Loss) Per Share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,371,891	7,124,091	5,235,278
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)		$17.62	$22.09
Deferred Stock Units (DSUs) [Member]
Note 5 - Income (Loss) Per Share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	503,010

Note_5_Income_Loss_Per_Share_D1

Note 5 - Income (Loss) Per Share (Details) - Calculation of Basic and Diluted Net Income (Loss) Per Common Share (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Basic and dilutive numerator:
Net income (loss) (in Dollars)	($2,521)	($5,379)	($1,180)	($1,619)	$1,829	($160)	$7,810	$2,383	($10,699)	$11,862	$18,094
Denominator:
Common shares outstanding									41,957	38,705	38,578
Contingently issuable shares - vested DSUs										7	2
Weighted-average common shares outstanding—basic	44,648	44,644	39,767	38,769	38,724	38,709	38,708	38,707	41,957	38,712	38,580
Net effect of dilutive securities:
Stock options										104	241
Contingently issuable shares – nonvested DSUs										67	119
Weighted-average common shares outstanding—diluted	44,648	44,644	39,767	38,769	39,141	38,709	38,847	38,845	41,957	38,883	38,940
Net income (loss) per common share—basic (in Dollars per share)	($0.06)	($0.12)	($0.03)	($0.04)	$0.05	$0	$0.20	$0.06	($0.25)	$0.31	$0.47
Net income (loss) per common share—diluted (in Dollars per share)	($0.06)	($0.12)	($0.03)	($0.04)	$0.05	$0	$0.20	$0.06	($0.25)	$0.31	$0.46

Note_6_Segment_Reporting_Detai

Note 6 - Segment Reporting (Details)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Number of Reportable Segments	2

Note_6_Segment_Reporting_Detai1

Note 6 - Segment Reporting (Details) - Financial Information by Reporting Segment (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Net Revenue	$55,877	$59,711	$49,003	$45,870	$54,876	$59,318	$62,524	$52,963	$210,461	$229,681	$204,323
Gross profit (loss):
Gross Profit	11,960	11,791	14,996	12,509	19,629	20,280	27,489	19,558	51,256	86,956	90,303
Operating expenses									69,239	69,466	64,906
Income (loss) from operations									-17,983	17,490	25,397
Non-operating income (expenses)									-165	-263	481
Income (loss) before income taxes									-18,148	17,227	25,878
Finished Pharmaceutical Products Segment [Member]
Segment Reporting Information [Line Items]
Net Revenue									198,480	229,681	204,323
Gross profit (loss):
Gross Profit									52,724	86,956	90,303
Active Pharmaceutical Ingredient Segment [Member]
Segment Reporting Information [Line Items]
Net Revenue	5,897	5,982	102						11,981
Gross profit (loss):
Gross Profit	($1,172)	($331)	$35						($1,468)

Note_6_Segment_Reporting_Detai2

Note 6 - Segment Reporting (Details) - Net Revenues and Carrying Values of Long-Lived Assets of Enterprises by Geographic Regions (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Revenue	$55,877	$59,711	$49,003	$45,870	$54,876	$59,318	$62,524	$52,963	$210,461	$229,681	$204,323
Long-Lived Assets	138,289				116,619				138,289	116,619
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Revenue									198,480	229,681	204,323
Long-Lived Assets	102,313				99,398				102,313	99,398
CHINA
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	22,170				17,221				22,170	17,221
FRANCE
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Revenue									11,981
Long-Lived Assets	$13,806								$13,806

Note_7_Customer_and_Supplier_C2

Note 7 - Customer and Supplier Concentration (Details) - Accounts Receivable and Net Revenues Information for the Company’s Major Customers (Customer Concentration Risk [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Actavis, Inc. [Member] | Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Customer	18.00%	44.00%
Actavis, Inc. [Member] | Sales Revenue, Net [Member]
Revenue, Major Customer [Line Items]
Customer	30.00%	35.00%	35.00%
AmerisourceBergen [Member] | Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Customer	5.00%	11.00%
AmerisourceBergen [Member] | Sales Revenue, Net [Member]
Revenue, Major Customer [Line Items]
Customer	15.00%	15.00%	14.00%
Cardinal Health [Member] | Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Customer	15.00%	7.00%
Cardinal Health [Member] | Sales Revenue, Net [Member]
Revenue, Major Customer [Line Items]
Customer	14.00%	13.00%	13.00%
MannKind Corporation [Member] | Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Customer	21.00%
MannKind Corporation [Member] | Sales Revenue, Net [Member]
Revenue, Major Customer [Line Items]
Customer	2.00%
McKesson [Member] | Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Customer	13.00%	13.00%
McKesson [Member] | Sales Revenue, Net [Member]
Revenue, Major Customer [Line Items]
Customer	22.00%	26.00%	27.00%

Note_8_Fair_Value_Measurements2

Note 8 - Fair Value Measurements (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]
Assets, Fair Value Adjustment	$0	$0
Liabilities, Fair Value Adjustment	$0	$0

Note_8_Fair_Value_Measurements3

Note 8 - Fair Value Measurements (Details) - Fair Values of the Company’s Financial Assets and Liabilities Measured on a Recurring Basis (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Cash equivalents:
Money market accounts	$42,994	$41,183
Restricted short-term investments:
Certificates of deposit	1,495	1,325
Fair value measurement as of	44,489	42,508
Fair Value, Inputs, Level 1 [Member]
Cash equivalents:
Money market accounts	42,994	41,183
Restricted short-term investments:
Certificates of deposit	1,495	1,325
Fair value measurement as of	$44,489	$42,508

Note_9_Goodwill_and_Intangible2

Note 9 - Goodwill and Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Indefinite-Lived Trademarks	$29,200,000
Amortization of Intangible Assets	1,920,000	1,907,000	1,840,000
Cortrosyn [Member] | Product Rights [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Amortization of Intangible Assets	$1,800,000	$1,800,000	$1,800,000

Note_9_Goodwill_and_Intangible3

Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification (USD $)	0 Months Ended				12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]
Definite-lived intangible assets, Weighted-Average Life (Years)			11 years		12 years
Definite-lived intangible assets, Original Cost	$30,491		$30,496		$30,491		$30,496
Definite-lived intangible assets, Accumulated Amortization	21,715		19,838		21,715		19,838
Definite-lived intangible assets, Net Book Value	8,776		10,658		8,776		10,658
Indefinite-lived intangible assets, Subtotal, Weighted-Average Life (Years)				[1]		[1]
Indefinite-lived intangible assets, Subtotal, Original Cost	4,467		280		4,467		280	280
Indefinite-lived intangible assets, Subtotal, Net Book Value	4,467		280		4,467		280	280
Indefinite-lived intangible assets, Subtotal, Original Cost	33,789		29,505		33,789		29,505
Indefinite-lived intangible assets, Subtotal, Net Book Value	33,789		29,505		33,789		29,505
Balance, Weighted-Average Life (Years)		[1]		[1]
Balance, Original Cost	64,280		60,001		64,280		60,001
Balance, Accumulated Amortization	21,715		19,838		21,715		19,838
Balance, Net Book Value	42,565		40,163		42,565		40,163
Trademarks [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]
Indefinite-lived intangible assets, Weighted-Average Life (Years)				[1]		[1]
Indefinite-lived intangible assets, Original Cost	29,225		29,225		29,225		29,225
Indefinite-lived intangible assets, Net Book Value	29,225		29,225		29,225		29,225
Finished Pharmaceutical Products Segment [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]
Indefinite-lived intangible assets, Subtotal, Original Cost	280		280		280		280
Indefinite-lived intangible assets, Subtotal, Net Book Value	280		280		280		280
Active Pharmaceutical Ingredient Segment [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]
Indefinite-lived intangible assets, Subtotal, Original Cost	4,187				4,187
Indefinite-lived intangible assets, Subtotal, Net Book Value	4,187				4,187
AFP Customers Segment [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]
Indefinite-lived intangible assets, Subtotal, Weighted-Average Life (Years)						[1]
Indefinite-lived intangible assets, Subtotal, Original Cost	97				97
Indefinite-lived intangible assets, Subtotal, Net Book Value	97				97
Product Rights [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]
Definite-lived intangible assets, Weighted-Average Life (Years)			12 years		12 years
Definite-lived intangible assets, Original Cost	27,134		27,134		27,134		27,134
Definite-lived intangible assets, Accumulated Amortization	20,896		19,114		20,896		19,114
Definite-lived intangible assets, Net Book Value	6,238		8,020		6,238		8,020
Balance, Accumulated Amortization	20,896		19,114		20,896		19,114
Patents [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]
Definite-lived intangible assets, Weighted-Average Life (Years)			10 years		10 years
Definite-lived intangible assets, Original Cost	293		298		293		298
Definite-lived intangible assets, Accumulated Amortization	78		50		78		50
Definite-lived intangible assets, Net Book Value	215		248		215		248
Balance, Accumulated Amortization	78		50		78		50
Trademarks [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]
Definite-lived intangible assets, Weighted-Average Life (Years)			11 years		11 years
Definite-lived intangible assets, Original Cost	19		19		19		19
Definite-lived intangible assets, Accumulated Amortization	15		13		15		13
Definite-lived intangible assets, Net Book Value	4		6		4		6
Balance, Accumulated Amortization	15		13		15		13
Land-Use Rights [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]
Definite-lived intangible assets, Weighted-Average Life (Years)			39 years		39 years
Definite-lived intangible assets, Original Cost	2,540		2,540		2,540		2,540
Definite-lived intangible assets, Accumulated Amortization	221		156		221		156
Definite-lived intangible assets, Net Book Value	2,319		2,384		2,319		2,384
Balance, Accumulated Amortization	221		156		221		156
Other Intangible Assets [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]
Definite-lived intangible assets, Weighted-Average Life (Years)			1 year		1 year
Definite-lived intangible assets, Original Cost	505		505		505		505
Definite-lived intangible assets, Accumulated Amortization	505		505		505		505
Balance, Accumulated Amortization	$505		$505		$505		$505
[1]	Intangible assets with indefinite lives have an undeterminable average life.

Note_9_Goodwill_and_Intangible4

Note 9 - Goodwill and Intangible Assets (Details) - Goodwill (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2012
Goodwill [Abstract]
Beginning balance	$280	$280
Goodwill related to acquisition of business	4,369
Currency translation and other adjustments	-182
Ending Balance	$4,467	$280

Note_9_Goodwill_and_Intangible5

Note 9 - Goodwill and Intangible Assets (Details) - Future Amortization Expense (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Future Amortization Expense [Abstract]
2015	$1,878
2016	1,878
2017	1,877
2018	986
2019	95
Thereafter	2,062
Total amortizable intangible assets	8,776	10,658
Indefinite-lived intangibles	33,789	29,505
Total intangibles (net of accumulated amortization)	$42,565	$40,163

Note_10_Inventories_Details_An

Note 10 - Inventories (Details) - Analysis of Inventories (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Analysis of Inventories [Abstract]
Raw materials and supplies	$41,996	$34,470
Work in process	16,221	14,698
Finished goods	24,755	26,501
Total inventory	82,972	75,669
Less reserve for excess and obsolete inventories	-640	-5,753
Total inventory, net	$82,332	$69,916

Note_11_Property_Plant_and_Equ2

Note 11 - Property, Plant, and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 11 - Property, Plant, and Equipment (Details) [Line Items]
Depreciation	$12,528,000	$11,171,000	$9,657,000
Interest Costs Capitalized	1,200,000	100,000	300,000
Property, Plant and Equipment, Gross	240,840,000	207,194,000
Primatene Mist HFA Manufacturing Equipment [Member]
Note 11 - Property, Plant, and Equipment (Details) [Line Items]
Property, Plant and Equipment, Gross	$3,400,000	$3,400,000

Note_11_Property_Plant_and_Equ3

Note 11 - Property, Plant, and Equipment (Details) - Property, Plant, and Equipment (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Abstract]
Building	$67,760	$58,898
Leasehold improvements	23,960	23,834
Land	7,020	5,805
Machinery and equipment	104,819	93,617
Furniture, fixtures, and automobiles	12,213	9,355
Construction in progress	25,068	15,685
Total property, plant, and equipment	240,840	207,194
Less accumulated depreciation and amortization	-102,551	-90,575
Total property, plant, and equipment, net	$138,289	$116,619

Note_12_Impairment_of_LongLive1

Note 12 - Impairment of Long-Lived Assets (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure Text Block Supplement [Abstract]
Impairment of Long-Lived Assets Held-for-use	$439	$126	$2,094

Note_13_Debt_Details

Note 13 - Debt (Details)

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Jun. 01, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Jan. 13, 2015

Jan. 05, 2015

Jan. 05, 2015

Apr. 22, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2010

Dec. 31, 2014

Dec. 31, 2014

Sep. 15, 2006

Dec. 31, 2014

Nov. 15, 2010

Dec. 31, 2014

Mar. 15, 2013

Dec. 31, 2014

Apr. 22, 2014

Mar. 05, 2007

Apr. 22, 2014

Apr. 22, 2014

Dec. 31, 2014

Apr. 22, 2014

Mar. 05, 2012

Jul. 31, 2013

Jul. 05, 2013

Apr. 10, 2012

Dec. 31, 2014

Dec. 31, 2013

Apr. 10, 2012

Mar. 05, 2012

15-May-09

Dec. 31, 2014

Apr. 30, 2014

Apr. 30, 2014

Dec. 31, 2014

Dec. 31, 2014

Apr. 30, 2014

Dec. 31, 2014

USD ($)

USD ($)

Building at Rancho Cucamonga, California [Member]

Building at Rancho Cucamonga, California [Member]

Building at Chino California Member

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Scenario, Refinanced [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Line of Credit Facility - Due March 2016 [Member]

Line of Credit Facility - Due January 2019 [Member]

Line of Credit Facility - Due January 2019 [Member]

Revolving Line of Credit - Due May 2016 [Member]

Revolving Line of Credit - Due May 2016 [Member]

Revolving Line of Credit - Due May 2016 [Member]

Revolving Line of Credit - Due May 2016 [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Cathay Bank [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Line of Credit Facility - Due January 2019 [Member]

Secured Debt [Member]

Mortgage Payable - Due January 2016 [Member]

Mortgage Payable - Due January 2016 [Member]

Mortgage Payable - Due January 2016 [Member]

Mortgage Payable - Due September 2016 [Member]

Mortgage Payable - Due September 2016 [Member]

Mortgage Payable - Due September 2016 [Member]

Equipment Loan - Due November 2014 [Member]

Equipment Loan - Due November 2014 [Member]

Equipment Loan - Due April 2017 [Member]

Equipment Loan - Due April 2017 [Member]

Mortgage Payable - Due April 2021 [Member]

Mortgage Payable - Due April 2021 [Member]

Mortgage Payable - Due April 2021 [Member]

Acquisition Loan - Due April 2019 [Member]

Acquisition Loan - Due April 2019 [Member]

Acquisition Loan - Due April 2019 [Member]

Acquisition Loan - Due April 2019 [Member]

Line of Credit [Member]

Line of Credit [Member]

Line of Credit [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

East West Bank [Member]

East West Bank [Member]

Minimum [Member]

USD ($)

EUR (€)

USD ($)

EUR (€)

Mortgage Payable - Due January 2016 [Member]

Mortgage Payable - Due September 2016 [Member]

Mortgage Payable - Due January 2016 [Member]

Equipment Loan Due January 2019 [Member]

Equipment Loan Due January 2019 [Member]

Line of Credit [Member]

Mortgage Payable - Due April 2021 [Member]

Minimum [Member]

East West Bank [Member]

East West Bank [Member]

London Interbank Offered Rate (LIBOR) [Member]

East West Bank [Member]

East West Bank [Member]

Minimum [Member]

East West Bank [Member]

Minimum [Member]

East West Bank [Member]

Cathay Bank [Member]

Cathay Bank [Member]

Cathay Bank [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

East West Bank [Member]

Prime Rate [Member]

East West Bank [Member]

Minimum [Member]

Cathay Bank [Member]

Cathay Bank [Member]

Cathay Bank [Member]

USD ($)

USD ($)

East West Bank [Member]

East West Bank [Member]

East West Bank [Member]

East West Bank [Member]

East West Bank [Member]

East West Bank [Member]

Cathay Bank [Member]

East West Bank [Member]

USD ($)

USD ($)

East West Bank [Member]

USD ($)

USD ($)

East West Bank [Member]

USD ($)

East West Bank [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Minimum [Member]

Cathay Bank [Member]

Cathay Bank [Member]

Cathay Bank [Member]

USD ($)

East West Bank [Member]

USD ($)

Cathay Bank [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Cathay Bank [Member]

USD ($)

Note 13 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$6,200,000

$6,200,000

$4,600,000

$4,500,000

$2,800,000

$3,200,000

$4,900,000

$5,300,000

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

3,800,000

2,200,000

3,900,000

12,000,000

Number of Buildings Securing Loan

1

1

1

Debt Instrument, Interest Rate, Stated Percentage

4.48%

4.48%

5.00%

5.00%

3.50%

5.42%

4.00%

4.00%

4.00%

Debt Instrument, Basis Spread on Variable Rate

2.50%

0.25%

Line of Credit Facility, Maximum Borrowing Capacity

8,000,000

10,000,000

8,000,000

20,000,000

8,000,000

8,000,000

Long-term Line of Credit

6,200,000

15,000,000

Debt Instrument, Periodic Payment

28,100

Debt Instrument, Fair Value Disclosure

4,800,000

Long-term Debt, Gross

4,500,000

21,900,000

Line of Credit Facility, Fair Value of Amount Outstanding

0

Debt Instrument, Maturity Date

22-Apr-19

Debt Instrument, Term

120 months

Debt Instrument Loan Collateral Percentage

65.00%

Business Combination, Consideration Transferred, Liabilities Incurred

16,000,000

11,600,000

Business Acquisition Purchase Price Obligation Term

4 years

4 years

Business Acquisition Interest On Purchase Price Obligation State Percentage

3.00%

Payment of Commitment Obligation Related to Business Acquisition

6,000,000

4,900,000

Long-term Debt and Capital Lease Obligations

36,106,000

10,069,000

8,200,000

6,900,000

undefined

1.2

undefined

1.5

Capital Leased Assets, Gross

1,500,000

1,500,000

Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation

$400,000

$200,000

Note_13_Debt_Details_Debt_Cons

Note 13 - Debt (Details) - Debt Consists of the Following (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]
Long Term Debt	$42,678
Payment obligation to Merck	8,160
Equipment under Capital Leases	1,022	1,258
Total debt and capital leases	43,700	32,173
Less current portion of long-term debt and capital leases	7,594	22,104
Long-term debt, net of current portion and capital leases	36,106	10,069
Mortgage Payable - Due January 2016 [Member] | Secured Debt [Member] | East West Bank [Member]
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]
Long Term Debt	3,887	4,041
Mortgage Payable - Due September 2016 [Member] | Secured Debt [Member] | East West Bank [Member]
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]
Long Term Debt	2,289	2,364
Equipment Loan - Due November 2014 [Member] | Secured Debt [Member] | East West Bank [Member]
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]
Long Term Debt		783
Equipment Loan - Due April 2017 [Member] | Secured Debt [Member] | East West Bank [Member]
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]
Long Term Debt	2,923	4,103
Mortgage Payable - Due April 2021 [Member] | Secured Debt [Member] | Cathay Bank [Member]
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]
Long Term Debt	4,549	4,624
Revolving Line of Credit - Due May 2016 [Member] | Revolving Credit Facility [Member] | Cathay Bank [Member]
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]
Line of Credit		15,000
Acquisition Loan - Due April 2019 [Member] | Cathay Bank [Member]
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]
Long Term Debt	$20,870

Note_13_Debt_Details_LongTerm_

Note 13 - Debt (Details) - Long-Term Debt Maturities (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Long-Term Debt Maturities [Abstract]
2015	$7,243
2015	403
2016	12,973
2016	301
2017	3,131
2017	298
2018	2,203
2018	126
2019	13,076
Thereafter	4,052
	42,678
	1,128
Less amount representing interest	106
	42,678
	1,022
	$43,700

Note_14_Income_Taxes_Details

Note 14 - Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 30, 2014
Note 14 - Income Taxes (Details) [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$15,400,000
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	2,900,000
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	8,437,000	6,987,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	9,863,000	7,751,000
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax	447,000	406,000
Deferred Tax Assets, Valuation Allowance	3,862,000
Deferred Tax Liabilities, Undistributed Foreign Earnings	-10,500,000	-5,000,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	4,300,000
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions	1,900,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	100,000	100,000
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions			-1,200,000
Unrecognized Tax Benefits, Income Tax Penalties Expense			0
Domestic Tax Authority [Member] | Tax Year 2011 [Member]
Note 14 - Income Taxes (Details) [Line Items]
Open Tax Year	2011
Domestic Tax Authority [Member] | Tax Year 2012 [Member]
Note 14 - Income Taxes (Details) [Line Items]
Open Tax Year	2012
Domestic Tax Authority [Member] | Tax Year 2013 [Member]
Note 14 - Income Taxes (Details) [Line Items]
Open Tax Year	2013
State and Local Jurisdiction [Member] | Earliest Tax Year [Member]
Note 14 - Income Taxes (Details) [Line Items]
Open Tax Year	2007
State and Local Jurisdiction [Member] | Latest Tax Year [Member]
Note 14 - Income Taxes (Details) [Line Items]
Open Tax Year	2013
Tax Year 2007 [Member] | California Franchise Tax Board [Member]
Note 14 - Income Taxes (Details) [Line Items]
Income Tax Examination, Year under Examination	2007
Tax Year 2008 [Member] | California Franchise Tax Board [Member]
Note 14 - Income Taxes (Details) [Line Items]
Income Tax Examination, Year under Examination	2008
Tax Year 2009 [Member] | California Franchise Tax Board [Member]
Note 14 - Income Taxes (Details) [Line Items]
Income Tax Examination, Year under Examination	2009
Intangible Deferred Tax Asset [Member]
Note 14 - Income Taxes (Details) [Line Items]
Deferred Tax Assets, Valuation Allowance				4,400,000
California Franchise Tax Board [Member]
Note 14 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	15,500,000
Operating Loss Carryforwards Expiration Year	2029
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	15,800,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	7,200,000
Other States Taxing Agencies [Member]
Note 14 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	1,600,000
Operating Loss Carryforwards Expiration Year	2030
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	100,000
Internal Revenue Service (IRS) [Member]
Note 14 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards Expiration Year	2034
Deferred Tax Assets, Tax Credit Carryforwards, Research	2,700,000
Tax Credit Carryforward Expiration Year	2031
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax	$400,000

Note_14_Income_Taxes_Details_I

Note 14 - Income Taxes (Details) - Income Before Tax, Domestic and Foreign (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income (loss) before income taxes:
United States	($12,946)	$20,116	$27,715
Foreign	-5,202	-2,889	-1,837
Total income (loss) before taxes	($18,148)	$17,227	$25,878

Note_14_Income_Taxes_Details_P

Note 14 - Income Taxes (Details) - Provision (Benefit) for Income Taxes (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current provision (benefit):
Federal	($131)	$3,306	($1,304)
State	193	541	-2,337
Foreign	1,388	104	94
Total current provision (benefit)	1,450	3,951	-3,547
Deferred provision (benefit):
Federal	-4,309	2,254	11,817
State	-1,699	227	170
Foreign	-2,891	-1,067	-656
Total deferred provision (benefit)	-8,899	1,414	11,331
Total provision (benefit) for income taxes	($7,449)	$5,365	$7,784

Note_14_Income_Taxes_Details_I1

Note 14 - Income Taxes (Details) - Income Tax Rate Reconciliation	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Rate Reconciliation [Abstract]
Statutory federal income tax (benefit)	-35.00%	35.00%	35.00%
State tax expense, net of federal tax benefit	-5.40%	2.90%	-4.70%
Foreign income tax	1.80%	0.30%	0.10%
Qualified production activities deduction		-3.30%
Research and development credits	-6.40%	-9.90%
Benefit for uncertain tax position			-3.00%
ISO portion of stock options deductions	4.00%	6.30%	4.00%
Other		-0.20%	-1.30%
Effective tax rate (benefit)	-41.00%	31.10%	30.10%

Note_14_Income_Taxes_Details_D

Note 14 - Income Taxes (Details) - Deferred Tax Assets and Liabilities (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Net operating loss carryforward	$7,877	$933
State income taxes	270	290
Inventory capitalization and reserve	6,843	5,800
Deferred revenue	864	1,151
Accrued payroll and benefits	1,571	1,465
Share-based compensation	8,437	6,987
Research and development credits	9,863	7,751
Alternative minimum tax	447	406
Bad debt reserve	67	57
Intangibles	3,861
Accrued for workers’ compensation insurance	864	776
Product return allowance	1,221	2,092
Total deferred tax assets	47,545	35,780
Deferred tax liabilities:
Depreciation/amortization	15,649	13,920
Intangibles	4,753	3,828
Federal impact of state deferred taxes	2,910	2,397
Other	937	575
Total deferred tax liabilities	24,249	20,720
Valuation Allowance	3,862
Net deferred tax assets	19,434	15,060
Accrued Professional Fees [Member]
Deferred tax assets:
Accrued	568	885
Accrued Chargebacks [Member]
Deferred tax assets:
Accrued	$4,792	$7,187

Note_14_Income_Taxes_Details_U

Note 14 - Income Taxes (Details) - Unrecognized Tax Benefits (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Unrecognized Tax Benefits [Abstract]
Balance at the beginning of the year	$4,186	$3,532
Balance at the end of the year	4,783	4,186
Additions based on tax positions related to the current year	655	766
Deductions based on tax audit settlement		-93
Deductions based on statute of limitations	($58)	($19)

Note_15_Stockholders_Equity_De

Note 15 - Stockholders' Equity (Details) (USD $)	0 Months Ended	12 Months Ended			1 Months Ended
	Jun. 25, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2015	Dec. 31, 2014	Nov. 06, 2014	Jun. 05, 2014
Note 15 - Stockholders' Equity (Details) [Line Items]
Proceeds from Issuance Initial Public Offering, Net of Issuance Costs (in Dollars)	$34,700,000
Common Stock, Shares Authorized		300,000,000	300,000,000			300,000,000		300,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)		$0.00	$0.00			0.0001		$0.00
Preferred Stock, Shares Authorized		20,000,000	20,000,000			20,000,000		20,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)		$0.00	$0.00			0.0001		$0.00
Preferred Stock, Shares Issued		0	0			0
Preferred Stock, Shares Outstanding		0	0			0
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		5 years
Stock Repurchase Program, Authorized Amount (in Dollars)							10,000,000
Treasury Stock, Shares, Acquired		29,400
Stock Repurchased During Period, Value (in Dollars)		300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		4 years 226 days	4 years 321 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 years	4 years 6 months	4 years 292 days
Assumed Forfeiture Rates Used in Estimates		8.00%	8.00%	9.00%		8.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%	0.00%	0.00%
Allocated Share-based Compensation Expense (in Dollars)		9,280,000	7,035,000	7,425,000
Share-based Compensation Arrangement by Share-based Payment Award, Deferred Stock Units, Number of Shares of Common Stock Per Award		1				1
IPO [Member] | Underwriter [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	1,200,000
IPO [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	5,840,000
Share Price (in Dollars per share)	$7
Proceeds from Issuance Initial Public Offering (in Dollars)	40,900,000
Payments of Stock Issuance Costs (in Dollars)	6,200,000
Employee Stock Option [Member] | Maximum [Member] | Existing Employees [Member] | The 2005 Plan [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		5 years
Employee Stock Option [Member] | Maximum [Member] | The 2005 Plan [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 years
Employee Stock Option [Member] | Minimum [Member] | Existing Employees [Member] | The 2005 Plan [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Employee Stock Option [Member] | New Employees [Member] | The 2005 Plan [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Employee Stock Option [Member] | The 2005 Plan [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)		11,900,000				11,900,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 109 days
Employee Stock Option [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Allocated Share-based Compensation Expense (in Dollars)		6,700,000	5,900,000	6,500,000
Deferred Stock Units (DSUs) [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Allocated Share-based Compensation Expense (in Dollars)		2,000,000	600,000	500,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 146 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options (in Dollars)		$5,800,000				5,800,000
Share-based Compensation Arrangement By Share Based Payment Award Options Expiring			76,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exchanged in Period			20,374
Subsequent Event [Member] | The 2005 Plan [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized					892,936
Maximum [Member] | The 2005 Plan [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term		5 years
Minimum [Member] | The 2005 Plan [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term		3 years
The 2005 Plan [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Equity Incentive Plan Potential Increase In Shares		2.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		2,300,000				2,300,000
2014 Employee Stock Purchase Plan [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Employe Stock Purchase Plan ESPP, Offering Duration, Maximum						27 months
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date						85.00%
Employee Stock Purchase Plan ESPP Number of Shares Available for Future Issuance		2,000,000

Note_15_Stockholders_Equity_De1

Note 15 - Stockholders' Equity (Details) - Weighted-Averages for Key Assumptions Used in Determining the Fair Value of Options Granted	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Weighted-Averages for Key Assumptions Used in Determining the Fair Value of Options Granted [Abstract]
Average volatility	29.90%	28.60%	32.60%
Risk-free interest rate	1.70%	1.30%	0.70%
Weighted-average expected life in years	5 years	4 years 6 months	4 years 292 days
Dividend yield rate	0.00%	0.00%	0.00%

Note_15_Stockholders_Equity_De2

Note 15 - Stockholders' Equity (Details) - Summary of Option Activity (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Summary of Option Activity [Abstract]
Outstanding	10,771,755		8,278,766
Outstanding	$15.39		$18
Outstanding	11,371,891		10,771,755
Outstanding	$15.12		$15.39
Outstanding	4 years 226 days		4 years 321 days
Outstanding	$1,815	[1]	$20,343	[2]
Exercisable	6,281,300		5,154,201
Exercisable	$16.95		$18.86
Exercisable	3 years 197 days		3 years 135 days
Exercisable	$871	[1]	$5,756	[2]
Options granted	1,661,862		3,598,725
Options granted	$15.04		$12.09
Options exercised	-65,000		-4,200
Options exercised	$10.79		$13.07
Options cancelled	-135,398		-403,370
Options cancelled	$15.74		$12.88
Options expired	-861,328		-698,166
Options expired	$18.48		$30.84
[1]	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company's common stock for those awards that have an exercise price below the estimated fair value at December 31, 2014.
[2]	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company's common stock for those awards that have an exercise price below the estimated fair value at December 31, 2013.

Note_15_Stockholders_Equity_De3

Note 15 - Stockholders' Equity (Details) - Option Grants and Exercises (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Option Grants and Exercises [Abstract]
Weighted-average grant date fair value (in Dollars per share)	$4.02	$2.79	$3.01
Intrinsic value of options exercised	$144		$1,546
Cash received	571	55	333
Total fair value of the options vested during the year	$6,407	$6,067	$6,809

Note_15_Stockholders_Equity_De4

Note 15 - Stockholders' Equity (Details) - Summary of Nonvested Options (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary of Nonvested Options [Abstract]
Nonvested	5,617,554	3,849,866
Nonvested	$3.12	$4.01
Nonvested	5,090,591	5,617,554	3,849,866
Nonvested	$3.34	$3.12	$4.01
Options granted	1,661,862	3,598,725
Options granted	$4.02	$2.79	$3.01
Options vested	-2,053,427	-1,427,667
Options vested	$3.12	$4.25
Options forfeited	-135,398	-403,370
Options forfeited	$5.60	$4.13

Note_15_Stockholders_Equity_De5

Note 15 - Stockholders' Equity (Details) - Information Relating to DSU Grants and Deliveries (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Deferred Stock Units (DSUs) [Member]
Note 15 - Stockholders' Equity (Details) - Information Relating to DSU Grants and Deliveries [Line Items]
Total DSUs Issued	503,010		98,495		111,731
Total DSUs Issued	456,406		100,675	[1]
Total DSUs Issued - DSUs forfeited	-994		-20,048
Total DSUs Issued - DSUs surrendered for taxes	-10,670		-13,783
Common stock delivered	-40,227		-80,080
Deferred Stock Units Issued as Compensation [Member]
Note 15 - Stockholders' Equity (Details) - Information Relating to DSU Grants and Deliveries [Line Items]
Total Fair Market Value of DSUs Issued as Compensation (in Dollars)	6,474	[2]	1,000	[1],[2]
[1]	76,000 total expiring options were exchanged for 20,374 DSUs, in aggregate in 2013.
[2]	The total FMV is derived from the number of DSUs granted times the current stock price on the date of grant.

Note_15_Stockholders_Equity_De6

Note 15 - Stockholders' Equity (Details) - Share-based Compensation Expense Under all Plans (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share base compensation	$9,280	$7,035	$7,425
Cost Of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share base compensation	1,678	1,503	1,794
Selling, Distribution And Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share base compensation	137	132	143
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share base compensation	6,800	4,701	4,593
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share base compensation	$665	$699	$895

Note_16_Employee_Benefits_Deta

Note 16 - Employee Benefits (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%
Defined Contribution Plan, Maximum Employer Matching Per Employee, Percent	2.00%
Defined Contribution Plan, Employer Contribution Vesting Period	4 years
Defined Contribution Plan, Employer Discretionary Contribution Amount	$0.70	$0.60	$0.50
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	1.75%
Defined Benefit Plan, Benefit Obligation	1.1
Pension Expense	0.2
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), before Tax	$0.20

Note_17_Commitments_and_Contin2

Note 17 - Commitments and Contingencies (Details)

9 Months Ended

12 Months Ended

1 Months Ended

80 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2012

Dec. 31, 2014

Nov. 30, 2012

Jan. 31, 2010

Nov. 30, 2012

31-May-05

Dec. 31, 2011

Jan. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Jul. 31, 2014

USD ($)

USD ($)

USD ($)

ANP [Member]

Agreements With a Chinese Governmental Entity [Member]

Agreements With a Chinese Governmental Entity [Member]

Agreements With a Chinese Governmental Entity [Member]

Exclusive Marketing Rights for Enoxaparin [Member]

Exclusive Marketing Rights for Enoxaparin [Member]

Exclusive Marketing Rights for Enoxaparin [Member]

Exclusive Marketing Rights for Enoxaparin [Member]

Exclusive Marketing Rights for Enoxaparin [Member]

Land-Use Rights [Member]

Land-Use Rights [Member]

Insuling Supply Agreement With MannKind [Member]

Insuling Supply Agreement With MannKind [Member]

Insuling Supply Agreement With MannKind [Member]

Insuling Supply Agreement With MannKind [Member]

Research and Development Arrangement [Member]

Minimum [Member]

Maximum [Member]

Commitments to Purchase Equipment and Raw Materials [Member]

MannKind Corporation [Member]

Agreements With a Chinese Governmental Entity [Member]

Land-Use Rights [Member]

Land-Use Rights [Member]

USD ($)

Andrx Pharmaceuticals, Inc. [Member]

Andrx Pharmaceuticals, Inc. [Member]

Watson Pharmaceuticals, Inc. [Member]

Watson Pharmaceuticals, Inc. [Member]

Watson Pharmaceuticals, Inc. [Member]

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Note 17 - Commitments and Contingencies (Details) [Line Items]

Proceeds from Customers

$4,500,000

Deferred Revenue, Period for Recognition

7 years

Recognition of Deferred Revenue

4,500,000

Distribution Agreement With Corporate Partner, Renewal Option Period

3 years

Deferred Revenue

2,600,000

3,300,000

13,400,000

11,000,000

14,000,000

11,000,000

Supply Commitment, Remaining Minimum Amount Committed

146,000,000

120,100,000

Long-term Supply Commitment, Optional Renewal Period

2 years

Lessee Leasing Arrangements, Operating Leases, Renewal Term

1 year

6 years

Operating Leases, Rent Expense

3,100,000

3,100,000

3,900,000

Long-term Purchase Commitment, Amount

6,800,000

Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures

45,000,000

Registered Capital Commitment to Subsidiary

61,000,000

Contractual Obligation

8,160,000

16,000,000

15,000,000

Finite-Lived Intangible Assets, Gross

30,496,000

30,491,000

1,300,000

1,200,000

2,540,000

2,540,000

Purchase Commitments Amount Fulfilled

$7,200,000

Note_17_Commitments_and_Contin3

Note 17 - Commitments and Contingencies (Details) - Future Minimum Rental Payments (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Future Minimum Rental Payments [Abstract]
2015	$2,585
2016	1,552
2017	1,356
2018	843
2019	675
	$7,011

Note_18_Litigation_Details

Note 18 - Litigation (Details) (Enoxaparin Patent Litigation [Member], Momenta and Sandoz [Member], USD $)	0 Months Ended	12 Months Ended	0 Months Ended
	Oct. 31, 2011	Dec. 31, 2014	Jan. 24, 2014	Sep. 21, 2011
Pending Litigation [Member]
Note 18 - Litigation (Details) [Line Items]
Number of Alleged Patent Infringements				2
Litigation, Plaintiff Preliminary Injunction Bond, Amount	$100,100,000
Loss Contingency, Damages Sought, Value		100,100,000
Judicial Ruling [Member]
Note 18 - Litigation (Details) [Line Items]
Litigation Settlement, Expense			$40,000

Note_19_Subsequent_Event_Detai

Note 19 - Subsequent Event (Details) (East West Bank [Member], USD $)	Jan. 13, 2015	Jan. 05, 2015	Jul. 05, 2013
Subsequent Event [Member] | Secured Debt [Member] | Equipment Loan Due January 2019 [Member]
Note 19 - Subsequent Event (Details) [Line Items]
Debt Instrument, Face Amount	$6,200,000	$6,200,000
Debt Instrument, Interest Rate, Stated Percentage	4.48%	4.48%
Subsequent Event [Member] | Line of Credit Facility - Due January 2019 [Member] | Line of Credit [Member]
Note 19 - Subsequent Event (Details) [Line Items]
Long-term Line of Credit		6,200,000
Line of Credit Facility, Maximum Borrowing Capacity		8,000,000
Line of Credit Facility - Due January 2019 [Member] | Line of Credit [Member]
Note 19 - Subsequent Event (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$8,000,000

Note_20_Quarterly_Financial_Da2

Note 20 - Quarterly Financial Data (Unaudited) (Details) - Quarterly Financial Data (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 20 - Quarterly Financial Data (Unaudited) (Details) - Quarterly Financial Data [Line Items]
Net revenues	$55,877	$59,711	$49,003	$45,870	$54,876	$59,318	$62,524	$52,963	$210,461	$229,681	$204,323
Gross profit	11,960	11,791	14,996	12,509	19,629	20,280	27,489	19,558	51,256	86,956	90,303
Net loss	-2,521	-5,379	-1,180	-1,619	1,829	-160	7,810	2,383	-10,699	11,862	18,094
Basic (in Shares)	44,648	44,644	39,767	38,769	38,724	38,709	38,708	38,707	41,957	38,712	38,580
Diluted (in Shares)	44,648	44,644	39,767	38,769	39,141	38,709	38,847	38,845	41,957	38,883	38,940
Basic (in Dollars per share)	($0.06)	($0.12)	($0.03)	($0.04)	$0.05	$0	$0.20	$0.06	($0.25)	$0.31	$0.47
Diluted (in Dollars per share)	($0.06)	($0.12)	($0.03)	($0.04)	$0.05	$0	$0.20	$0.06	($0.25)	$0.31	$0.46
Finished Pharmaceutical Products [Member]
Note 20 - Quarterly Financial Data (Unaudited) (Details) - Quarterly Financial Data [Line Items]
Net revenues	49,980	53,729	48,901	45,870	54,876	59,318	62,524	52,963
Gross profit	13,132	12,122	14,961	12,509	19,629	20,280	27,489	19,558
Active Pharmaceutical Ingredient Segment [Member]
Note 20 - Quarterly Financial Data (Unaudited) (Details) - Quarterly Financial Data [Line Items]
Net revenues	5,897	5,982	102						11,981
Gross profit	($1,172)	($331)	$35						($1,468)